<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003092" GROUP_ID="PREG" ID="007900030114043880" MERGED_FROM="" MODIFIED="2009-09-25 13:23:31 +0200" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Notes for reviewers:&lt;br&gt;1. Please ensure that you are familiar with the generic protocol before starting on your review.&lt;br&gt;2. Please complete the background and modify the rest of the text to be relevant to this review.&lt;br&gt;3. Data extraction from the original trial reports will be done centrally, and you will be supplied with copies of the trials and the completed data extraction forms between the end of March and mid-April.&lt;br&gt;4. Please check that you are happy with the data extraction, and contact authors of trial reports for any clarification needed.&lt;br&gt;5. Please enter the data into the tables, which have already been constructed in this template. &lt;br&gt;6. Please note that you should only include those outcomes with data in the analysis tables as described in the generic protocol.&lt;br&gt;7. After completing the analysis, complete the text of the review and the abstract.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-09-25 12:21:22 +0100" NOTES_MODIFIED_BY="Sonja L  Henderson" REVIEW_NO="0316" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2009-09-25 13:23:31 +0200" MODIFIED_BY="Sonja Henderson">
<TITLE>Extra-amniotic prostaglandin for induction of labour</TITLE>
<CONTACT MODIFIED="2009-09-25 13:23:31 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="15922" ROLE="AUTHOR"><FIRST_NAME>Eileen</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Hutton</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Associate Professor/Assistant Dean, Midwifery</POSITION><EMAIL_1>huttone@mcmaster.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1200 Main Street West, MDCL 2215</ADDRESS_1><CITY>Hamilton</CITY><ZIP>L8N 3Z5</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 5259140 Ext 26654</PHONE_1><FAX_1>+1 905 5236459</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-09-25 13:23:31 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="15922" ROLE="AUTHOR"><FIRST_NAME>Eileen</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Hutton</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Associate Professor/Assistant Dean, Midwifery</POSITION><EMAIL_1>huttone@mcmaster.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1200 Main Street West, MDCL 2215</ADDRESS_1><CITY>Hamilton</CITY><ZIP>L8N 3Z5</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 5259140 Ext 26654</PHONE_1><FAX_1>+1 905 5236459</FAX_1></ADDRESS></PERSON><PERSON ID="15970" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ellen</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Mozurkewich</LAST_NAME><POSITION>Assistant Professor, Maternal-Fetal Medicine</POSITION><EMAIL_1>mozurk@umich.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>University of Michigan</ORGANISATION><ADDRESS_1>F4835, Box 0264 Mott Hospital</ADDRESS_1><ADDRESS_2>1500 E. Medical Center Drive</ADDRESS_2><CITY>Ann Arbor</CITY><ZIP>48109-0264</ZIP><REGION>MI</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 734 7641406</PHONE_1><FAX_1>+1 734 6471006</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-07-27 15:05:54 +0100" MODIFIED_BY="Sonja L  Henderson" NOTES="&lt;p&gt;Minor update: 8/19/05&lt;/p&gt;&lt;p&gt;New studies found but not yet included or excluded: 7/1/01&lt;/p&gt;" NOTES_MODIFIED="2009-07-27 15:05:54 +0100" NOTES_MODIFIED_BY="Sonja L  Henderson">
<UP_TO_DATE>
<DATE DAY="30" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="6" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="11" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2009-09-24 17:09:16 +0100" MODIFIED_BY="Sonja L  Henderson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-09-24 17:09:16 +0100" MODIFIED_BY="Sonja L  Henderson">
<DATE DAY="22" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>Corrections made re: reporting error in 'Results' of 'Abstract' and addition of text inadvertently missed from last update in 'Effects of interventions' section. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-09-24 16:59:53 +0100" MODIFIED_BY="Sonja L  Henderson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-09-24 16:59:53 +0100" MODIFIED_BY="Sonja L  Henderson">
<DATE DAY="30" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated. Two new studies (<LINK REF="STD-Allouche-1993" TYPE="STUDY">Allouche 1993</LINK>; <LINK REF="STD-Majoko-2002a" TYPE="STUDY">Majoko 2002a</LINK>) added and one excluded (<LINK REF="STD-Fletcher-1993" TYPE="STUDY">Fletcher 1993</LINK>). </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-24 11:17:16 +0100" MODIFIED_BY="Sonja L  Henderson">
<DATE DAY="14" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-11-18 19:45:09 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2008-11-18 19:45:09 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2008-11-18 19:45:09 +0000" MODIFIED_BY="[Empty name]">
<NAME>Canadian Institutes of Health Research New Investigator Award</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION>
<P>Hutton is a reciepient of the CIHR New Scholar Award; a salary grant award supporting research.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-09-25 12:21:22 +0100" MODIFIED_BY="Sonja L  Henderson">
<SUMMARY MODIFIED="2009-07-27 15:20:20 +0100" MODIFIED_BY="Sonja L  Henderson">
<TITLE MODIFIED="2008-04-14 14:16:44 +0100" MODIFIED_BY="[Empty name]">Extra-amniotic prostaglandin for induction of labour</TITLE>
<SUMMARY_BODY MODIFIED="2009-07-27 15:20:20 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Not enough evidence to show any benefit of extra-amniotic prostaglandin for the induction of labour over other methods.</P>
<P>Sometimes it is necessary to start labour artificially because of safety concerns for the mother or baby. Drugs can be given as a gel placed inside the vagina or cervix or inside the uterine cavity in the space between the uterine wall and the amniotic sac. This gel is put in place using a catheter. Prostaglandins are drugs that are used to ripen the cervix or help start labour. The review of twelve trials compared different methods of giving prostaglandin to start labour. Extra-amniotic prostaglandin was found to be effective, but it is more invasive than other methods. There was not enough evidence to show benefits of extra-amniotic prostaglandin over other methods.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-09-24 17:01:30 +0100" MODIFIED_BY="Sonja L  Henderson">
<ABS_BACKGROUND>
<P>This is one of a series of reviews of methods of cervical ripening and labour induction using standardised methodology.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effects of extra-amniotic prostaglandin for third trimester cervical ripening or induction of labour.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-08-03 10:20:18 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2009) and bibliographies of relevant papers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-07-24 11:31:44 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Randomised and quasi-randomised trials comparing extra-amniotic prostaglandin used for third trimester cervical ripening or labour induction with placebo/no treatment or other methods listed above it on a predefined list of labour induction methods.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-07-24 11:31:59 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Two review authors independently assessed eligibility and carried out data extraction for all reports identified by the search strategy.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-09-24 17:01:30 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Twelve studies are included. Of the primary outcomes, there were significantly fewer women delivered vaginally within 24 hours among those induced with extra-amniotic prostaglandin (PG) F2 alpha compared to vaginal misoprostol (risk ratio (RR) 2.43; 95% confidence interval (CI) 1.42 to 4.15). No other differences between groups for primary outcomes were found to be statistically significant. Oxytocin was used to initiate or augment labour significantly less frequently with extra-amniotic prostaglandins when compared to placebo (RR 0.51; 95% CI 0.39 to 0.67) but significantly more frequently when compared to vaginal misoprostol (RR 1.73; 95% CI 1.20 to 2.49). When extra-amniotic PGE2 was compared to Foley catheter only, the only difference between groups was that there were fewer cases of unfavourable cervix at 12 to 24 hours following treatment (RR 0.59; 95% CI 0.41 to 0.86). Women receiving extra-amniotic prostaglandin were more likely to be satisfied (mean difference 4.40; 95% CI 3.50 to 5.30) and less likely to be embarrassed by the treatment compared to vaginal PGE2 (RR 8.91; 95% CI 2.26 to 35.02). There were no other significant differences when extra-amniotic prostaglandins were compared with other methods of cervical ripening or induction of labour. Although this could suggest that extra-amniotic prostaglandins are as effective as other agents, the findings are difficult to interpret because they are based on very small numbers and may lack the power to show a real difference.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-07-28 08:45:14 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>The studies in this review are limited by sample size which are often divided into multiple comparison groups. Most comparisons showed no significant differences, with wide confidence intervals. Although extra-amniotic prostaglandins may be as effective as other modalities in initiating labour, there is little conclusive information from this review to guide clinical practice. An adequately powered randomised controlled trial would be useful to determine if the use of extra-amniotic prostaglandins would lower the rate of caesarean section.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-09-25 12:21:22 +0100" MODIFIED_BY="Sonja L  Henderson">
<BACKGROUND MODIFIED="2009-07-24 15:45:18 +0100" MODIFIED_BY="[Empty name]">
<P>Sometimes it is necessary to bring on labour artificially because of safety concerns for the mother or baby. This review is one of a series of reviews of methods of labour induction using a standardised protocol. For more detailed information on the rationale for this methodological approach, please refer to the currently published 'generic' protocol (<LINK REF="REF-Hofmeyr-2000" TYPE="REFERENCE">Hofmeyr 2000</LINK>). The generic protocol describes how a number of standardised reviews will be combined to compare various methods of preparing the cervix of the uterus and inducing labour. The studies included in this review are primarily concerned with the action of extra-amniotic prostaglandins as cervical ripening agents in preparation for induction of labour.</P>
<P>Prostaglandins have been used since the early 1970s as cervical ripening agents in the 'pre-induction management' of women requiring induction of labour, but presenting with an unripe or unfavourable cervix. When induction is undertaken with an unripe cervix, there is a higher rate of failed induction and an ensuing increased rate of caesarean delivery. Amniotomy is often used with oxytocin to facilitate induction and is believed to be associated with the release of endogenous prostaglandins which promote cervical ripening. However, this procedure can be uncomfortable, difficult, or impossible with a closed cervix and has the disadvantage of imposing a time limit on the induction process.<BR/>
<BR/>Of the prostaglandins that have been used for ripening and induction, it is believed that PGE2 acts primarily on cervical tissues, while PGF2alpha acts on both the cervical and myometrial tissues. The characteristics of an ideal cervical ripening agent include the ability to act on the cervix without myometrial action (including contractions). Extra-amniotic placement of prostaglandins was first undertaken in the early 1970s and has been largely replaced with cervical or vaginal placement. Although there are reports of prostaglandin tablets being introduced into the extra-vaginal space, all the studies included in the review use prostaglandin gel, with one exception which uses prostaglandin in a saline solution (0.5 micrograms/ml), applied via a Foley catheter at a rate of 1 ml/min (<LINK REF="STD-Sherman-2001" TYPE="STUDY">Sherman 2001</LINK>). When prostaglandin gel is used it is placed via a Foley catheter inserted through the cervix into the extra-amniotic space, and in most studies the catheter is left in place with the balloon inflated, with or without application of traction on the balloon by way of taping the Foley to the maternal leg.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine, from the best available evidence, the effectiveness and safety of extra-amniotic prostaglandin for third trimester cervical ripening and induction of labour.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-03 12:08:21 +0100" MODIFIED_BY="Sonja L  Henderson">
<SELECTION_CRITERIA MODIFIED="2009-07-27 15:16:30 +0100" MODIFIED_BY="Sonja L  Henderson">
<CRIT_STUDIES MODIFIED="2009-07-24 15:45:45 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical trials comparing extra-amniotic prostaglandin for cervical ripening or labour induction, with placebo/no treatment or other methods listed above it on a predefined list of methods of labour induction have been reviewed. All included trials incorporated some form of random allocation to either group and they reported one or more of the prestated outcomes (<I>see</I> '<LINK TAG="DATA_COLLECTION" TYPE="SECTION">Data collection and analysis</LINK>').</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-07-24 15:45:51 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant women due for third trimester induction of labour, carrying a viable fetus were included.</P>
<P>Predefined subgroup analyses including nulliparity or multiparity; and cervix unfavourable, favourable or undefined, have been done. Only those outcomes with data appear in the analysis tables.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-07-27 15:15:17 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Extra-amniotic prostaglandin compared with placebo/no treatment or several other methods for labour induction or preparation for labour induction, which are placed above extra-amniotic prostaglandin on a predefined list of methods of labour induction. The comparisons included in the studies in this review included:<BR/>(i) placebo;<BR/>(ii) vaginal prostaglandins;<BR/>(iii) intracervical prostaglandins;<BR/>(iv) intravenous oxytocin;<BR/>(v) vaginal misoprostol;<BR/>(vi) mechanical methods (Foley catheter with traction).</P>
<P>For the details of this selection strategy please refer to the section: '<LINK TAG="METHODS" TYPE="SECTION">Methods</LINK>'.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-07-27 15:16:30 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Clinically relevant outcomes for trials of methods of cervical ripening/labour induction have been prespecified by two authors of labour induction reviews (Justus Hofmeyr and Zarko Alfirevic). Differences were settled by discussion.</P>
<P>Five primary outcomes were chosen as being most representative of the clinically important measures of effectiveness and complications. Sub-group analyses will be limited to the primary outcomes:<BR/>(1) vaginal delivery not achieved within 24 hours (or period specified by trial authors);<BR/>(2) uterine hyperstimulation with fetal heart rate (FHR) changes;<BR/>(3) caesarean section;<BR/>(4) serious neonatal morbidity or perinatal death (e.g. seizures, birth asphyxia defined by trialists, neonatal encephalopathy, disability in childhood);<BR/>(5) serious maternal morbidity or death (e.g. uterine rupture, admission to intensive care unit, septicaemia).</P>
<P>Perinatal and maternal morbidity and mortality are composite outcomes. This is not an ideal solution because some components are clearly less severe than others. It is possible for one intervention to cause more deaths but less severe morbidity. However, in the context of labour induction at term this is unlikely. All these events will be rare, and a modest change in their incidence will be easier to detect if composite outcomes are presented. The incidence of individual components will be explored as secondary outcomes (<I>see</I> below).</P>
<P>Secondary outcomes relate to measures of effectiveness, complications and satisfaction:</P>
<P>Measures of effectiveness:<BR/>(6) cervix unfavourable/unchanged after 12 to 24 hours;<BR/>(7) oxytocin augmentation.</P>
<P>Complications:<BR/>(8) uterine hyperstimulation without FHR changes;<BR/>(9) uterine rupture;<BR/>(10) epidural analgesia;<BR/>(11) instrumental vaginal delivery;<BR/>(12) meconium-stained liquor;<BR/>(13) Apgar score less than seven at five minutes;<BR/>(14) neonatal intensive care unit admission;<BR/>(15) neonatal encephalopathy;<BR/>(16) perinatal death;<BR/>(17) disability in childhood;<BR/>(18) maternal side-effects (all);<BR/>(19) maternal nausea;<BR/>(20) maternal vomiting;<BR/>(21) maternal diarrhoea;<BR/>(22) other maternal side-effects;<BR/>(23) postpartum haemorrhage (as defined by the trial authors);<BR/>(24) serious maternal complications (e.g. intensive care unit admission, septicaemia but excluding uterine rupture);<BR/>(25) maternal death.</P>
<P>Measures of satisfaction:<BR/>(26) woman not satisfied;<BR/>(27) caregiver not satisfied.</P>
<P>'Uterine rupture' includes all clinically significant ruptures of unscarred or scarred uteri. Trivial scar dehiscence noted incidentally at the time of surgery are excluded.</P>
<P>Additional outcomes may appear in individual primary reviews, but will not contribute to the secondary reviews.</P>
<P>While all the above outcomes were sought, only those with data appear in the analysis tables.</P>
<P>The terminology of uterine hyperstimulation is problematic (<LINK REF="REF-Curtis-1987" TYPE="REFERENCE">Curtis 1987</LINK>). In the reviews we use the term 'uterine hyperstimulation without FHR changes' to include uterine tachysystole (more than five contractions per 10 minutes for at least 20 minutes) and uterine hypersystole/hypertonus (a contraction lasting at least two minutes) and 'uterine hyperstimulation with FHR changes' to denote uterine hyperstimulation syndrome (tachysystole or hypersystole with FHR changes such as persistent decelerations, tachycardia or decreased short-term variability).</P>
<P>Outcomes were included in the analysis if reasonable measures were taken to minimise observer bias and data were available for analysis according to original allocation.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-03 10:20:37 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-08-03 10:20:37 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (June 2009).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords. </P>
<P>The search for the first version of this review was performed simultaneously for all reviews of methods of inducing labour, as outlined in the generic protocol for these reviews (<LINK REF="REF-Hofmeyr-2000" TYPE="REFERENCE">Hofmeyr 2000</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-20 14:47:30 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the reference lists of trial reports and reviews by hand.</P>
<P>We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-03 12:08:21 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>To avoid duplication of data the labour induction methods have been listed in a specific order, from one to 27. Each review includes comparisons between one of the methods (from two to 27) with only those methods above it on the list. Thus, the review of intravenous oxytocin (4) will include only comparisons with intracervical prostaglandins (3), vaginal prostaglandins (2) or placebo (1). Methods identified in the future will be added to the end of the list. The current list is as follows:</P>
<OL>
<LI>placebo/no treatment;</LI>
<LI>vaginal prostaglandins (<LINK REF="REF-Kelly-2003" TYPE="REFERENCE">Kelly 2003</LINK>);</LI>
<LI>intracervical prostaglandins (<LINK REF="REF-Boulvain-2008" TYPE="REFERENCE">Boulvain 2008</LINK>);</LI>
<LI>intravenous oxytocin (<LINK REF="REF-Kelly-2001" TYPE="REFERENCE">Kelly 2001</LINK>);</LI>
<LI>amniotomy (<LINK REF="REF-Bricker-2000" TYPE="REFERENCE">Bricker 2000</LINK>);</LI>
<LI>intravenous oxytocin with amniotomy (<LINK REF="REF-Howarth-2001" TYPE="REFERENCE">Howarth 2001</LINK>);</LI>
<LI>vaginal misoprostol (<LINK REF="REF-Hofmeyr-2003" TYPE="REFERENCE">Hofmeyr 2003</LINK>);</LI>
<LI>oral misoprostol (<LINK REF="REF-Alfirevic-2006" TYPE="REFERENCE">Alfirevic 2006</LINK>)</LI>
<LI>mechanical methods including extra-amniotic Foley catheter (<LINK REF="REF-Boulvain-2001" TYPE="REFERENCE">Boulvain 2001</LINK>);</LI>
<LI>membrane sweeping (<LINK REF="REF-Boulvain-2005" TYPE="REFERENCE">Boulvain 2005</LINK>);</LI>
<LI>extra-amniotic prostaglandins (<LINK REF="REF-Hutton-2001" TYPE="REFERENCE">Hutton 2001</LINK>);</LI>
<LI>intravenous prostaglandins (<LINK REF="REF-Luckas-2000" TYPE="REFERENCE">Luckas 2000</LINK>);</LI>
<LI>oral prostaglandins (<LINK REF="REF-French-2001" TYPE="REFERENCE">French 2001</LINK>);</LI>
<LI>mifepristone (<LINK REF="REF-Neilson-2000" TYPE="REFERENCE">Neilson 2000</LINK>);</LI>
<LI>estrogens (<LINK REF="REF-Thomas-2001" TYPE="REFERENCE">Thomas 2001</LINK>);</LI>
<LI>corticosteroids (<LINK REF="REF-Kavanagh-2006" TYPE="REFERENCE">Kavanagh 2006</LINK>);</LI>
<LI>relaxin (<LINK REF="REF-Kelly-2001a" TYPE="REFERENCE">Kelly 2001a</LINK>);</LI>
<LI>hyaluronidase (<LINK REF="REF-Kavanagh-2006a" TYPE="REFERENCE">Kavanagh 2006a</LINK>);</LI>
<LI>castor oil, bath, and/or enema (<LINK REF="REF-Kelly-2001b" TYPE="REFERENCE">Kelly 2001b</LINK>);</LI>
<LI>acupuncture (<LINK REF="REF-Smith-2004" TYPE="REFERENCE">Smith 2004</LINK>);</LI>
<LI>breast stimulation (<LINK REF="REF-Kavanagh-2005" TYPE="REFERENCE">Kavanagh 2005</LINK>);</LI>
<LI>sexual intercourse (<LINK REF="REF-Kavanagh-2001" TYPE="REFERENCE">Kavanagh 2001</LINK>);</LI>
<LI>homeopathic methods (<LINK REF="REF-Smith-2003" TYPE="REFERENCE">Smith 2003</LINK>);</LI>
<LI>nitric oxide donors (<LINK REF="REF-Kelly-2008" TYPE="REFERENCE">Kelly 2008</LINK>);</LI>
<LI>buccal or sublingual misoprostol (<LINK REF="REF-Muzonzini-2004" TYPE="REFERENCE">Muzonzini 2004</LINK>)</LI>
<LI>hypnosis; </LI>
<LI>other methods for induction of labour.</LI>
</OL>
<P>The reviews will be analysed by the following subgroups:</P>
<OL>
<LI>previous caesarean section or not;</LI>
<LI>nulliparity or multiparity;</LI>
<LI>membranes intact or ruptured;</LI>
<LI>cervix favourable, unfavourable or undefined.</LI>
</OL>
<P>For most reviews, the initial data extraction process was conducted centrally. This was co-ordinated from the Clinical Effectiveness Support Unit (CESU) at the Royal College of Obstetricians and Gynaecologists, UK, in co-operation with the Pregnancy and Childbirth Group of the Cochrane Collaboration. This process allowed the data extraction process to be standardised across all the reviews. From 2001, the data extraction was no longer conducted centrally.</P>
<P>The trials were initially reviewed on eligibility criteria, using a standardised form and the basic selection criteria specified above. Following this, data were extracted to a standardised data extraction form which was piloted for consistency and completeness. The pilot process involved the researchers at the CESU and previous review authors in the area of induction of labour.</P>
<P>Information was extracted regarding the methodological quality of trials on a number of levels. This process completed without consideration of trial results. Assessment of selection bias examined the process involved in the generation of the random sequence and the method of allocation concealment separately. These were then judged as adequate or inadequate using the criteria described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the purpose of the reviews.</P>
<P>Performance bias was examined with regards to whom was blinded in the trials, i.e. patient, caregiver, outcome assessor or analyst. In many trials the caregiver, assessor and analyst were the same party. Details of the feasibility and appropriateness of blinding at all levels is sought.</P>
<P>Individual outcome data were included in the analysis if they met the prestated criteria in <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>. Included trial data were processed as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). Data extracted from the trials were analysed on an intention-to-treat basis (when this was not done in the original report, re-analysis was performed if possible). Where data were missing, clarification is sought from the original authors. If the attrition was such that it might significantly affect the results, these data have been excluded from the analysis. Once missing data become available, they will be included in the analyses.</P>
<P>Data were extracted from all eligible trials to examine how issues of quality influence effect size in a sensitivity analysis. In trials where reporting is poor, methodological issues are reported as unclear or clarification sought.</P>
<P>Due to the large number of trials, double data extraction was not feasible and agreement between the three data extractors was therefore assessed on a random sample of trials.</P>
<P>Once the data had been extracted, they were distributed to individual review authors for entry onto the Review Manager computer software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>), checked for accuracy, and analysed as above using the RevMan software. For dichotomous data, risk ratios and 95% confidence intervals are calculated, and in the absence of heterogeneity, results are pooled using a fixed-effect model.</P>
<P>The predefined criteria for sensitivity analysis include all aspects of quality assessment as mentioned above, including aspects of selection, performance and attrition bias.</P>
<P>Primary analysis was limited to the prespecified outcomes and subgroup analyses. In the event of differences in unspecified outcomes or sub-groups being found, these were analysed post hoc, but clearly identified as such to avoid drawing unjustified conclusions.</P>
<P>In 2008, the methods and software for carrying out reviews were updated, as a result of which new reviews and updates, where appropriate, will use these new methods (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; <LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>), which will be described in the Methods section of all the individual new and updated reviews.</P>
<P>For this update, we used the following methods when assessing the trials identified by the updated search.</P>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of methodological quality of included studies</HEADING>
<P>We assessed the validity of each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We described methods used for generation of the randomisation sequence for each trial.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Selection bias (randomisation and allocation concealment)</HEADING>
<P>We assigned a quality score for each trial, using the following criteria:</P>
<UL>
<LI>adequate concealment of allocation: such as telephone randomisation, consecutively-numbered, sealed opaque envelopes;</LI>
<LI>unclear whether adequate concealment of allocation: such as list or table used, sealed envelopes, or study does not report any concealment approach;</LI>
<LI>inadequate concealment of allocation: such as open list of random-number tables, use of case record numbers, dates of birth or days of the week.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Attrition bias (loss of participants, for example, withdrawals, dropouts, protocol deviations)</HEADING>
<P>We assessed completeness to follow up using the following criteria:</P>
<UL>
<LI>less than 5% loss of participants;</LI>
<LI>5% to 9.9% loss of participants;</LI>
<LI>10% to 19.9% loss of participants;</LI>
<LI>more than 20% loss of participants.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Performance bias (blinding of participants, researchers and outcome assessment)</HEADING>
<P>We assessed blinding using the following criteria:<BR/>(1) blinding of participants (yes/no/unclear);<BR/>(2) blinding of caregiver (yes/no/unclear);<BR/>(3) blinding of outcome assessment (yes/no/unclear).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of treatment effect</HEADING>
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>). We used fixed-effect meta-analysis for combining data in the absence of significant heterogeneity if trials were sufficiently similar. If heterogeneity was found, we explored this by sensitivity analysis, followed by random-effects if required.</P>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we used the mean difference if outcomes are measured in the same way between trials. We used the standardised mean difference to combine trials that measure the same outcome, but use different methods. Where there was evidence of skewness, this has been reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dealing with missing data</HEADING>
<P>We analysed data on all participants with available data in the group to which they were allocated, regardless of whether or not they received the allocated intervention. If, in the original reports, participants were not analysed in the group to which they were randomised and there is sufficient information in the trial report, we attempted to restore them to the correct group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity</HEADING>
<P>We applied tests of heterogeneity between trials, if appropriate, using the I<SUP>2</SUP> statistic. If we identified high levels of heterogeneity among the trials (exceeding 50%), we explored it by prespecified subgroup analysis and performed sensitivity analysis. We used a random-effects meta-analysis as an overall summary if this is considered appropriate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>We conducted planned subgroup analyses as performed for the other reviews in this series (<I>see</I> <LINK TAG="DATA_COLLECTION" TYPE="SECTION">Data collection and analysis</LINK>). When assessing differences between sub groups e.g. within the comparison of vaginal PGE2 versus placebo, we explored this using an inverse variance method of meta analysis and presenting the statistics for subgroup differences using chi square and I<SUP>2</SUP> statistics.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>We did not carry out sensitivity analysis because the number of studies was too small in any one analysis to justify this step.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-09-25 12:21:22 +0100" MODIFIED_BY="Sonja L  Henderson">
<STUDY_DESCRIPTION MODIFIED="2009-07-27 15:17:05 +0100" MODIFIED_BY="Sonja L  Henderson">
<SUBSECTION>
<HEADING LEVEL="3">Excluded studies</HEADING>
<P>Nine studies have been excluded. <LINK REF="STD-Salamalekis-1990" TYPE="STUDY">Salamalekis 1990</LINK>, <LINK REF="STD-Toppozada-1994" TYPE="STUDY">Toppozada 1994</LINK> and <LINK REF="STD-Tsalacopoulo-1982" TYPE="STUDY">Tsalacopoulo 1982</LINK> were excluded because the entry criterion for the study was intrauterine death. Several studies were excluded because they reported none of the primary outcomes of interest (<LINK REF="STD-Calder-1974" TYPE="STUDY">Calder 1974</LINK>; <LINK REF="STD-Fletcher-1993" TYPE="STUDY">Fletcher 1993</LINK>; <LINK REF="STD-Keirse-1982" TYPE="STUDY">Keirse 1982</LINK>; <LINK REF="STD-Reichel-1985" TYPE="STUDY">Reichel 1985</LINK>; <LINK REF="STD-Thiery-1981" TYPE="STUDY">Thiery 1981</LINK>; <LINK REF="STD-Thoumsin-1982" TYPE="STUDY">Thoumsin 1982</LINK>). For one additional study, we are awaiting confirmation that the data are original (<LINK REF="STD-Majoko-2002b" TYPE="STUDY">Majoko 2002b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<P>Twelve studies are included in this review.</P>
<P>PGF2alpha was studied in three of the trials (<LINK REF="STD-Mahomed-1988" TYPE="STUDY">Mahomed 1988</LINK>; <LINK REF="STD-Majoko-2002a" TYPE="STUDY">Majoko 2002a</LINK>; <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>) and the remaining studies used PGE2. In all of the included studies the prostaglandin introduced into the extra-amniotic space was in a gel preparation, with one exception which used prostaglandin in a saline solution (0.5 micrograms/ml), applied via Foley catheter at a rate of 1 ml/min (<LINK REF="STD-Sherman-2001" TYPE="STUDY">Sherman 2001</LINK>). Neither <LINK REF="STD-Parewicjk-1986" TYPE="STUDY">Parewicjk 1986</LINK>, <LINK REF="STD-Shepherd-1976" TYPE="STUDY">Shepherd 1976</LINK>, nor <LINK REF="STD-Wilson-1978" TYPE="STUDY">Wilson 1978</LINK> report on how the prostaglandin gel was introduced into the extra-amniotic space. Of the remaining studies, <LINK REF="STD-Clarke-1980" TYPE="STUDY">Clarke 1980</LINK> and <LINK REF="STD-Fenton-1985" TYPE="STUDY">Fenton 1985</LINK> removed the catheter after insertion of the gel, while all others left the catheter in situ. Of the studies with the catheter remaining in situ, <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK> inflated the catheter balloon to 10 ml, <LINK REF="STD-Greer-1989" TYPE="STUDY">Greer 1989</LINK> and <LINK REF="STD-Stewart-1985" TYPE="STUDY">Stewart 1985</LINK> to 20 ml, while <LINK REF="STD-Mahomed-1988" TYPE="STUDY">Mahomed 1988</LINK> and <LINK REF="STD-Sherman-2001" TYPE="STUDY">Sherman 2001</LINK> inflated the catheter balloon to 30 ml; <LINK REF="STD-Majoko-2002a" TYPE="STUDY">Majoko 2002a</LINK> to 40 ml and <LINK REF="STD-Allouche-1993" TYPE="STUDY">Allouche 1993</LINK> to 50 ml. When a Foley catheter is used as a mechanical method of induction, it is usually inflated to 30 to 40 ml and left in place. One study (<LINK REF="STD-Allouche-1993" TYPE="STUDY">Allouche 1993</LINK>) administered 0.01% (0.5 mg) salbutamol prior to both the administration of PGE2 extra-amniotically and cervically.</P>
<P>There was a considerable variation in the interventions being compared to extra-amniotic prostaglandin including: vaginal PGE2 (<LINK REF="STD-Clarke-1980" TYPE="STUDY">Clarke 1980</LINK>; <LINK REF="STD-Greer-1989" TYPE="STUDY">Greer 1989</LINK>; <LINK REF="STD-Stewart-1985" TYPE="STUDY">Stewart 1985</LINK>; <LINK REF="STD-Wilson-1978" TYPE="STUDY">Wilson 1978</LINK>), vaginal PGE1 (misoprostol) (<LINK REF="STD-Majoko-2002a" TYPE="STUDY">Majoko 2002a</LINK>) intra-cervical PGE2 (<LINK REF="STD-Allouche-1993" TYPE="STUDY">Allouche 1993</LINK>; <LINK REF="STD-Parewicjk-1986" TYPE="STUDY">Parewicjk 1986</LINK>), oral PGE2 (<LINK REF="STD-Wilson-1978" TYPE="STUDY">Wilson 1978</LINK>), intravenous oxytocin (<LINK REF="STD-Wilson-1978" TYPE="STUDY">Wilson 1978</LINK>) extra-amniotic oestriol (<LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>), Foley catheter with traction (<LINK REF="STD-Allouche-1993" TYPE="STUDY">Allouche 1993</LINK>; <LINK REF="STD-Mahomed-1988" TYPE="STUDY">Mahomed 1988</LINK>) and placebo (<LINK REF="STD-Fenton-1985" TYPE="STUDY">Fenton 1985</LINK>; <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>; <LINK REF="STD-Shepherd-1976" TYPE="STUDY">Shepherd 1976</LINK>; <LINK REF="STD-Sherman-2001" TYPE="STUDY">Sherman 2001</LINK>).</P>
<P>Both the comparison with extra-amniotic oestriol (<LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>) and oral PGE2 (<LINK REF="STD-Wilson-1978" TYPE="STUDY">Wilson 1978</LINK>) have been excluded from this review, because they are below extra-amniotic prostaglandins on the pre-defined list of comparisons.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-07-27 15:19:46 +0100" MODIFIED_BY="Sonja L  Henderson">
<SUBSECTION>
<HEADING LEVEL="3">Randomisation</HEADING>
<P>Of the twelve studies included, six did not describe methods of randomisation (<LINK REF="STD-Greer-1989" TYPE="STUDY">Greer 1989</LINK>; <LINK REF="STD-Parewicjk-1986" TYPE="STUDY">Parewicjk 1986</LINK>; <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>; <LINK REF="STD-Sherman-2001" TYPE="STUDY">Sherman 2001</LINK>; <LINK REF="STD-Stewart-1985" TYPE="STUDY">Stewart 1985</LINK>; <LINK REF="STD-Wilson-1978" TYPE="STUDY">Wilson 1978</LINK> ), one used allocation by date of birth (<LINK REF="STD-Clarke-1980" TYPE="STUDY">Clarke 1980</LINK>), one used alternation (<LINK REF="STD-Shepherd-1976" TYPE="STUDY">Shepherd 1976</LINK>). The remaining five described adequate methods of random allocation and concealment of sequence (<LINK REF="STD-Allouche-1993" TYPE="STUDY">Allouche 1993</LINK>; <LINK REF="STD-Fenton-1985" TYPE="STUDY">Fenton 1985</LINK>; <LINK REF="STD-Mahomed-1988" TYPE="STUDY">Mahomed 1988</LINK>; <LINK REF="STD-Majoko-2002a" TYPE="STUDY">Majoko 2002a</LINK>; <LINK REF="STD-Sherman-2001" TYPE="STUDY">Sherman 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Several authors discussed the fact that given the nature of the interventions being compared blinding would be challenging (<LINK REF="STD-Mahomed-1988" TYPE="STUDY">Mahomed 1988</LINK>; <LINK REF="STD-Majoko-2002a" TYPE="STUDY">Majoko 2002a</LINK>; <LINK REF="STD-Wilson-1978" TYPE="STUDY">Wilson 1978</LINK>). Blinding is known to have been used in three of the trials (<LINK REF="STD-Fenton-1985" TYPE="STUDY">Fenton 1985</LINK>; <LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>; <LINK REF="STD-Sherman-2001" TYPE="STUDY">Sherman 2001</LINK>). Blinding was not discussed in any of the other studies. In the absence of blinding, there is a real possibility of bias particularly in clinical management decisions, which could impact on outcomes such as the number of vaginal deliveries not achieved within 24 hours, or caesarean section rates.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-09-25 12:21:22 +0100" MODIFIED_BY="Sonja L  Henderson">
<SUBSECTION>
<HEADING LEVEL="3">Extra-amniotic prostaglandin versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Extra-amniotic PGE2</HEADING>
<P>Three studies compared extra-amniotic PGE2 with placebo. <LINK REF="STD-Fenton-1985" TYPE="STUDY">Fenton 1985</LINK> (n = 30) enrolled nulliparous women with a Bishop's score of less than four at more than 36 weeks while <LINK REF="STD-Shepherd-1976" TYPE="STUDY">Shepherd 1976</LINK> (n = 30) and <LINK REF="STD-Sherman-2001" TYPE="STUDY">Sherman 2001</LINK> (n = 116) used the same cervical and gestational age criteria, but included multiparous women as well. <LINK REF="STD-Fenton-1985" TYPE="STUDY">Fenton 1985</LINK> and <LINK REF="STD-Shepherd-1976" TYPE="STUDY">Shepherd 1976</LINK> inserted the placebo via a Foley catheter and removed the catheter, while <LINK REF="STD-Sherman-2001" TYPE="STUDY">Sherman 2001</LINK> left the inflated Foley catheter in place following administration of the treatment and placebo.</P>
<SUBSECTION>
<HEADING LEVEL="5">(i) Primary outcomes</HEADING>
<P>All three studies of the above studies reported on caesarean section rates which averaged 10% with extra-amniotic PGE2 compared with 18% in the placebo group (risk ratio (RR) 0.56; 95% confidence interval (CI) 0.26 to 1.20). Only <LINK REF="STD-Shepherd-1976" TYPE="STUDY">Shepherd 1976</LINK> reported on hyperstimulation with fetal heart rate changes, and of the 15 women in each arm of the study, there were no cases reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(ii) Other outcomes</HEADING>
<P>Half as many women who received extra-amniotic PGE2 compared to placebo required oxytocin augmentation (40% versus 80%) (RR 0.51; 95% CI 0.39 to 0.67). There were no significant differences found between groups in instrumental vaginal delivery (RR 1.14; 95% CI 0.56 to 2.35) or in maternal side-effects (RR 1.52; 95% CI 0.55 to 4.23).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Extra-amniotic PGF2alpha</HEADING>
<P>One study (<LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK>) compared PGF2alpha with placebo. In this study 40 nulliparous women with a Bishop's score of less than four were randomly assigned to extra-amniotic application of either PGF2alpha (n = 15), or placebo gel (n = 10). All gel was inserted via a Foley catheter which was inflated to 10 cm and left in place.</P>
<SUBSECTION>
<HEADING LEVEL="5">(i) Primary outcomes</HEADING>
<P>The only primary outcome reported on was caesarean section, and there was no significant difference between the groups in this small study (RR 0.33; 95% CI 0.03 to 3.20).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(ii) Other outcomes</HEADING>
<P>
<LINK REF="STD-Quinn-1981" TYPE="STUDY">Quinn 1981</LINK> reported on maternal morbidity, uterine hyperstimulation without fetal heart rate change and instrumental vaginal delivery; there were no significant differences between groups. There was one reported perinatal death in the extra-amniotic PGF2alpha group.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Extra-amniotic prostaglandin E2 versus vaginal prostaglandin E2</HEADING>
<P>Four studies reported on extra-amniotic prostaglandin E2 versus vaginal prostaglandin E2 (<LINK REF="STD-Clarke-1980" TYPE="STUDY">Clarke 1980</LINK>; <LINK REF="STD-Greer-1989" TYPE="STUDY">Greer 1989</LINK>; <LINK REF="STD-Stewart-1985" TYPE="STUDY">Stewart 1985</LINK>; <LINK REF="STD-Wilson-1978" TYPE="STUDY">Wilson 1978</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">(i) Primary outcomes</HEADING>
<P>Only <LINK REF="STD-Clarke-1980" TYPE="STUDY">Clarke 1980</LINK> reported on vaginal delivery not achieved within 24 hours, and reported a risk ratio of 1.26 (95% CI 1.00 to 1.59). The remaining three studies reported no significant difference in caesarean section rates (RR 0.89; 95% CI 0.42 to 1.89).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(ii) Other outcomes</HEADING>
<P>Three studies (<LINK REF="STD-Greer-1989" TYPE="STUDY">Greer 1989</LINK>; <LINK REF="STD-Stewart-1985" TYPE="STUDY">Stewart 1985</LINK>; <LINK REF="STD-Wilson-1978" TYPE="STUDY">Wilson 1978</LINK>) reported no difference in instrumental vaginal delivery (RR 0.97; 95% CI 0.60 to 1.55). Greer and <LINK REF="STD-Stewart-1985" TYPE="STUDY">Stewart 1985</LINK> reported no difference in the need for oxytocin augmentation (RR 1.02; 95% CI 0.75 to 1.40).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Extra-amniotic prostaglandin E2 versus intracervical prostaglandin</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(i) Primary outcomes</HEADING>
<P>Only <LINK REF="STD-Parewicjk-1986" TYPE="STUDY">Parewicjk 1986</LINK> and <LINK REF="STD-Allouche-1993" TYPE="STUDY">Allouche 1993</LINK> compared extra-amniotic prostaglandin E2 versus intracervical prostaglandin and reported no significant difference in caesarean section rates (RR 0.75; 95% CI 0.43 to 1.30). <LINK REF="STD-Allouche-1993" TYPE="STUDY">Allouche 1993</LINK> reported one case of hyperstimulation with non-reassuring fetal heart rate in the intracervical prostaglandin group and none in the extra-amniotic group (RR 0.37; 95% CI 0.01 to 9.11).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Extra-amniotic prostaglandin E2 versus intravenous oxytocin</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(i) Primary outcomes</HEADING>
<P>
<LINK REF="STD-Wilson-1978" TYPE="STUDY">Wilson 1978</LINK> reported no difference in the caesarean section rate when comparing extra-amniotic prostaglandin E2 versus intravenous oxytocin (RR 0.20; 95% CI 0.03 to 1.51).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(ii) Other outcomes</HEADING>
<P>No significant difference was found in the rate of instrumental delivery for women receiving extra-amniotic prostaglandin E2 compared with intravenous oxytocin (RR 2.00; 95% CI 0.43 to 9.32).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Extra-amniotic prostaglandin versus mechanical methods (Foley catheter)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Extra-amniotic PGF2</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(i) Primary outcomes</HEADING>
<P>
<LINK REF="STD-Mahomed-1988" TYPE="STUDY">Mahomed 1988</LINK> reported no difference in caesarean section rates when extra-amniotic prostaglandin F2 was compared with Foley catheter (RR 1.03; 95% CI 0.53 to 1.99).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(ii) Other outcomes</HEADING>
<P>
<LINK REF="STD-Mahomed-1988" TYPE="STUDY">Mahomed 1988</LINK> also reported no differences between groups in the rate of oxytocin augmentation (RR 0.83; 95% CI .68 to 1.01), or instrumental vaginal delivery (RR 1.03; 95% CI 0.15 to 6.92) or in admissions to neonatal intensive care (RR 0.90; 95% CI 0.36 to 2.23).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Extra-amniotic PGF2 alpha versus vaginal misoprostol  </HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(i) Primary outcomes</HEADING>
<P>Comparing extra-amniotic PGF2  with vaginal misoprostol <LINK REF="STD-Majoko-2002a" TYPE="STUDY">Majoko 2002a</LINK> found an increased rate of vaginal delivery not occurring within 24 hours (RR 2.43; 95% CI 1.42 to 4.15) but no difference in caesarean section rates (RR 2.33; 95% CI 0.95 to 5.75). This study also reported no cases of serious maternal morbidity or death and found one case in each group of perinatal death.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(ii) Other outcomes</HEADING>
<P>
<LINK REF="STD-Majoko-2002a" TYPE="STUDY">Majoko 2002a</LINK> reported increased use of oxytocin augmentation in the extra-amniotic PGF2 group (RR 1.73; 95% CI 1.20 to 2.49) and no differences in meconium-stained liquor, neonatal intensive care unit admission, or postpartum haemorrhage.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-07-24 16:09:12 +0100" MODIFIED_BY="[Empty name]">
<P>All studies under review, have small sample sizes and only a small number of studies compare the same outcomes. When extra-amniotic PGE2 was compared to placebo, half as many women in the extra-amniotic PGE2 group required oxytocin augmentation (risk ratio 0.51; 95% confidence interval 0.40 to 0.68). This is the only finding where a significant difference was found in primary or secondary outcomes. Although the finding of no difference in comparisons with other induction modalities would suggest that extra-amniotic prostaglandins are as effective as the other modalities for the outcomes on which they were compared, the sample sizes were too small in all instances to draw conclusions, as evidenced by the wide confidence intervals associated with the findings.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-07-24 16:53:27 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-07-24 11:20:40 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Although extra-amniotic prostaglandins may be effective in pre-induction cervical preparation and induction, there was no evidence of an advantage over other methods of induction, in particular cervical and vaginal gels, or Foley catheter. There is minimal information about fetal safety or maternal side effects including infection. The need to introduce the gel though the cervix by way of a catheter may be considered more invasive than other methods from a woman's perspective, although more women appeared satisfied with the Foley approach compared to vaginal insertion.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-07-24 16:53:27 +0100" MODIFIED_BY="[Empty name]">
<P>It would have been useful for researchers to have undertaken appropriately sized randomised controlled trials to understand the role of extra-amniotic prostaglandins when they were first introduced. Extra-amniotic prostaglandins have been largely replaced in practice by other methods of prostaglandin administration and interest in undertaking an adequately sized randomised controlled trial at this time is less likely.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>None.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-11-18 19:42:49 +0000" MODIFIED_BY="[Empty name]">
<P>Both authors have reviewed the articles and extracted the data for this review. Hutton was the primary author, and Mozurkwich reviewed and edited the material.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-21 10:30:02 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-20 16:04:21 +0000" MODIFIED_BY="Lynn Hampson">
<INCLUDED_STUDIES MODIFIED="2008-11-20 16:04:21 +0000" MODIFIED_BY="Lynn Hampson">
<STUDY DATA_SOURCE="PUB" ID="STD-Allouche-1993" MODIFIED="2008-11-20 16:04:21 +0000" MODIFIED_BY="Lynn Hampson" NAME="Allouche 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-11-20 14:53:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allouche C, Dommesent D, Barjot P, Levy G</AU>
<TI>Cervical ripening: comparison of three methods. Preliminary results of a randomized prospective study</TI>
<TO>Maturations cervicales: comparaison de trois methodes. Resultats preliminaires d'une etude prospective randomisee</TO>
<SO>Revue Francaise de Gynecologie et d'Obstetrique</SO>
<YR>1993</YR>
<VL>88</VL>
<PG>492-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-20 14:56:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="BOOK">
<AU>Allouche C</AU>
<SO>Comparison of three methods of cervical ripening. Results of a prospective randomized trial [Comparaison de trois methodes de maturation cervicale: resultats d'une etude prospective randomisee]. [MD thesis]</SO>
<YR>1993</YR>
<PG>1-160</PG>
<PB>University of Caen, France</PB>
<CY>Caen, France</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-1980" MODIFIED="2008-06-09 09:14:41 +0100" MODIFIED_BY="Sonja Henderson" NAME="Clarke 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-06-09 09:14:41 +0100" MODIFIED_BY="Sonja Henderson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke GA, Letchworth AT, Noble AD</AU>
<TI>Comparative trial of extra-amniotic and vaginal prostaglandin E2 in tylose gel for induction of labor</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>1980</YR>
<VL>8</VL>
<PG>236-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fenton-1985" MODIFIED="2008-11-20 14:55:48 +0000" MODIFIED_BY="[Empty name]" NAME="Fenton 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-11-20 14:55:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fenton DW, Speedie J, Duncan SLB</AU>
<TI>Does cervical ripening with PGE2 affect subsequent uterine activity in labour?</TI>
<SO>Acta Obstetricia et Gynecologica Scandinavica</SO>
<YR>1985</YR>
<VL>64</VL>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greer-1989" MODIFIED="2008-11-20 14:57:11 +0000" MODIFIED_BY="[Empty name]" NAME="Greer 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greer IA, Calder AA</AU>
<TI>Pre-induction cervical ripening with extra-amniotic and vaginal prostaglandin E2</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1989</YR>
<VL>10</VL>
<PG>18-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-20 14:57:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Greer IA, Calder AA</AU>
<TI>Preinduction cervical ripening with extra-amniotic and vaginal prostaglandin E2</TI>
<SO>Proceedings of 1st European Congress on Prostaglandins in Reproduction; 1988 July 6-9; Vienna, Austria</SO>
<YR>1988</YR>
<PG>144</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahomed-1988" NAME="Mahomed 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mahomed K</AU>
<TI>Foley catheter under traction versus extra-amniotic prostaglandin gel in pre-treatment of unripe cervix - a randomised controlled trial</TI>
<SO>Central African Journal of Medicine</SO>
<YR>1988</YR>
<VL>34</VL>
<PG>98-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Majoko-2002a" MODIFIED="2008-11-20 15:43:12 +0000" MODIFIED_BY="Lynn Hampson" NAME="Majoko 2002a" YEAR="2002">
<REFERENCE MODIFIED="2008-11-20 15:42:50 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Majoko F, Zwizwai M, Lindmark G, Nystrom L</AU>
<TI>Labor induction with vaginal misoprostol and extra-amniotic prostaglandin F2 alpha gel</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2002</YR>
<VL>76</VL>
<PG>127-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parewicjk-1986" MODIFIED="2008-11-20 15:44:41 +0000" MODIFIED_BY="Lynn Hampson" NAME="Parewicjk 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-11-20 15:44:41 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Parewijck W, Thiery M</AU>
<TI>Cervical ripening: randomized comparative study of extra-amniotic vs intracervical PGE2 gel</TI>
<SO>Proceedings of 10th European Congress of Perinatal Medicine; 1986 Aug 12-16; Leipzig, Germany</SO>
<YR>1986</YR>
<PG>165</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Parewijck W</AU>
<TI>Cervical ripening: randomized study of extra-amniotic and intracervical prostaglandin E2 gel</TI>
<SO>Personal communication</SO>
<YR>1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quinn-1981" MODIFIED="2008-06-09 09:42:38 +0100" MODIFIED_BY="Sonja Henderson" NAME="Quinn 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-06-09 09:42:38 +0100" MODIFIED_BY="Sonja Henderson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quinn MA, Murphy AJ, Kuhn RJP, Robinson HP, Brown JB</AU>
<TI>A double blind trial of extra-amniotic oestriol and prostaglandin F2alpha gels in cervical ripening</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1981</YR>
<VL>88</VL>
<PG>644-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shepherd-1976" MODIFIED="2008-06-09 09:42:42 +0100" MODIFIED_BY="Sonja Henderson" NAME="Shepherd 1976" YEAR="1976">
<REFERENCE MODIFIED="2008-06-09 09:42:42 +0100" MODIFIED_BY="Sonja Henderson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shepherd J, Sims CD, Craft I</AU>
<TI>Extra-amniotic prostaglandin E2 and the unfavourable cervix</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>2</VL>
<PG>709-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sherman-2001" MODIFIED="2008-11-20 15:47:02 +0000" MODIFIED_BY="Lynn Hampson" NAME="Sherman 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-05 19:19:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherman DJ, Frenkel E, Pansky M, Caspi E, Bukovsy I, Langer R</AU>
<TI>Balloon cervical ripening with extra-amniotic infusion of saline or prostaglandin e2: a double-blind, randomized controlled study</TI>
<SO>Obstetrics and Gynaecology</SO>
<YR>2001</YR>
<VL>97</VL>
<NO>3</NO>
<PG>375-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-20 15:47:02 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherman DJ, Raaziel A, Arieli S, Bukovski I, Caspi E</AU>
<TI>Cervical ripening with extra-amniotic instillation (XAml) of saline and prostaglandin E2 (PGE2) solutions</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<PG>430</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stewart-1985" NAME="Stewart 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart P, Kennedy JH, Hillan E, Calder AA</AU>
<TI>The unripe cervix: management with vaginal or extra-amniotic prostaglandin E2</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1983</YR>
<VL>4</VL>
<PG>90-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Stewart P</AU>
<TI>Prostaglandins in the difficult induction</TI>
<SO>The role of prostaglandins in labour</SO>
<YR>1985</YR>
<PG>72-3</PG>
<ED>Wood C</ED>
<PB>RSM Services</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1978" MODIFIED="2008-06-09 09:42:54 +0100" MODIFIED_BY="Sonja Henderson" NAME="Wilson 1978" YEAR="1978">
<REFERENCE MODIFIED="2008-06-09 09:42:54 +0100" MODIFIED_BY="Sonja Henderson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson PD</AU>
<TI>A comparison of four methods of ripening the unfavourable cervix</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1978</YR>
<VL>85</VL>
<PG>941-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-20 15:55:45 +0000" MODIFIED_BY="Lynn Hampson">
<STUDY DATA_SOURCE="PUB" ID="STD-Calder-1974" MODIFIED="2008-06-09 09:43:05 +0100" MODIFIED_BY="Sonja Henderson" NAME="Calder 1974" YEAR="1974">
<REFERENCE MODIFIED="2008-06-09 09:43:05 +0100" MODIFIED_BY="Sonja Henderson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calder AA, Moar VA, Ounsted MK, Turnbull AC</AU>
<TI>Increased bilirubin levels in neonates after induction of labour by intravenous prostaglandin E2 or oxytocin</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>2</VL>
<PG>1339-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fletcher-1993" MODIFIED="2008-11-20 15:48:16 +0000" MODIFIED_BY="Lynn Hampson" NAME="Fletcher 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-11-20 15:48:12 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fletcher H, Mitchell S, Frederick J, Simeon D</AU>
<TI>Extra-amniotic misoprostol as a cervical ripening agent [abstract]</TI>
<SO>West Indian Medical Journal</SO>
<YR>1993</YR>
<VL>42</VL>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keirse-1982" MODIFIED="2008-11-20 15:48:48 +0000" MODIFIED_BY="Lynn Hampson" NAME="Keirse 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-11-20 15:48:48 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Keirse MJNC, Thiery M, Parewijck W, Mitchell MD</AU>
<TI>Extra-amniotic insertion of foreign materials to ripen the cervix has a durable effect on prostaglandin synthesis</TI>
<SO>Proceedings of 8th European Congress of Perinatal Medicine; 1982 Sept 7-10; Brussels, Belgium</SO>
<YR>1982</YR>
<PG>77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reichel-1985" MODIFIED="2008-11-20 15:49:09 +0000" MODIFIED_BY="Lynn Hampson" NAME="Reichel 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-11-20 15:49:09 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reichel R, Husslein P, Goschen K, Rasche M, Sinzinger, H</AU>
<TI>Resorption of prostaglandin e2 following various methods of local administration for ripening of the cervix and end the induction of labor</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1985</YR>
<VL>97</VL>
<PG>500-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salamalekis-1990" MODIFIED="2008-11-20 15:50:25 +0000" MODIFIED_BY="Lynn Hampson" NAME="Salamalekis 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-11-20 15:50:25 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Salamalekis E, Loghis C, Kassanos D, Traka A, Zourlas PA</AU>
<TI>Comparison of extra-amniotic prostaglandin F2alpha and dinoprostone use for labor induction after second trimester intrauterine fetal death</TI>
<SO>Proceedings of 12th European Congress of Perinatal Medicine; 1990 Sept 11-14; Lyon, France</SO>
<YR>1990</YR>
<PG>228</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thiery-1981" MODIFIED="2008-06-09 09:43:22 +0100" MODIFIED_BY="Sonja Henderson" NAME="Thiery 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-06-09 09:43:22 +0100" MODIFIED_BY="Sonja Henderson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thiery M, Parewijck W, Martens G, Derom R, Van Kets H</AU>
<TI>Extra-amniotic prostaglandin E2 gel vs amniotomy for elective induction of labour</TI>
<SO>Zeitschrift fur Geburtshilfe und Perinatologie</SO>
<YR>1981</YR>
<VL>185</VL>
<PG>323-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thoumsin-1982" MODIFIED="2008-11-20 15:49:49 +0000" MODIFIED_BY="Lynn Hampson" NAME="Thoumsin 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-11-20 15:49:49 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Thoumsin HJ, Renwart JP, Lambotte R</AU>
<TI>Cervical ripening and/or labour induction by extra-amniotic implantations of PGE2 tablets</TI>
<SO>Proceedings of 8th European Congress of Perinatal Medicine; 1982 Sept 7-10; Brussels, Belgium</SO>
<YR>1982</YR>
<PG>76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toppozada-1994" MODIFIED="2008-11-20 15:55:45 +0000" MODIFIED_BY="Lynn Hampson" NAME="Toppozada 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-11-20 15:55:45 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toppozada MK, Shaala SA, Anwar MY, Haiba NA, Abdrabbo S, El-Absy HM</AU>
<TI>Termination of pregnancy with fetal death in the second and third trimesters - the double balloon versus extra-amniotic prostaglandin</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>1994</YR>
<VL>45</VL>
<PG>269-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsalacopoulo-1982" MODIFIED="2008-06-09 09:43:35 +0100" MODIFIED_BY="Sonja Henderson" NAME="Tsalacopoulo 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-06-09 09:43:35 +0100" MODIFIED_BY="Sonja Henderson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsalacopoulos G, Bloch B, Rush JM</AU>
<TI>Intramuscular and extra-amniotic 15-(S)-15-methyl-prostaglandin F2alpha in intra-uterine death</TI>
<SO>South African Medical Journal</SO>
<YR>1982</YR>
<VL>61</VL>
<PG>825-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-11-20 16:01:39 +0000" MODIFIED_BY="Lynn Hampson">
<STUDY DATA_SOURCE="PUB" ID="STD-Majoko-2002b" MODIFIED="2008-11-20 16:01:39 +0000" MODIFIED_BY="Lynn Hampson" NAME="Majoko 2002b" YEAR="2002">
<REFERENCE MODIFIED="2008-11-20 15:58:02 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Majoko F. Zwizwai M, Nystom L. Lindmark G</AU>
<TI>Vaginal misoprostol for induction of labour: a more effective agent than prostaglandin f2 alpha gel and prostaglandin e2 pessary</TI>
<SO>Central African Journal of Medicine</SO>
<YR>2002</YR>
<VL>48</VL>
<NO>11-12</NO>
<PG>123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2008-08-05 19:45:17 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-21 10:30:02 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-21 10:30:02 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alfirevic-2006" MODIFIED="2008-11-21 10:03:40 +0000" MODIFIED_BY="[Empty name]" NAME="Alfirevic 2006" TYPE="COCHRANE_REVIEW">
<AU>Alfirevic Z, Weeks A</AU>
<TI>Oral misoprostol for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:03:40 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:03:40 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001338.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boulvain-2001" MODIFIED="2008-11-21 10:00:03 +0000" MODIFIED_BY="[Empty name]" NAME="Boulvain 2001" TYPE="COCHRANE_REVIEW">
<AU>Boulvain M, Kelly A, Lohse C, Stan C, Irion O</AU>
<TI>Mechanical methods for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-21 09:59:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 09:59:56 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001233"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boulvain-2005" MODIFIED="2008-11-21 10:03:04 +0000" MODIFIED_BY="[Empty name]" NAME="Boulvain 2005" TYPE="COCHRANE_REVIEW">
<AU>Boulvain M, Stan C, Irion O</AU>
<TI>Membrane sweeping for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:02:39 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:02:39 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000451.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Boulvain-2008" MODIFIED="2008-11-21 09:51:15 +0000" MODIFIED_BY="[Empty name]" NAME="Boulvain 2008" TYPE="COCHRANE_REVIEW">
<AU>Boulvain M, Kelly AJ, Irion O</AU>
<TI>Intracervical prostaglandins for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-11-21 09:42:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 09:42:45 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006971"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bricker-2000" MODIFIED="2008-11-21 09:46:48 +0000" MODIFIED_BY="[Empty name]" NAME="Bricker 2000" TYPE="COCHRANE_REVIEW">
<AU>Bricker L, Luckas M</AU>
<TI>Amniotomy alone for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-21 09:46:48 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 09:46:48 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002862"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Curtis-1987" NAME="Curtis 1987" TYPE="JOURNAL_ARTICLE">
<AU>Curtis P, Evans S, Resnick J</AU>
<TI>Uterine hyperstimulation. The need for standard terminology</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1987</YR>
<VL>32</VL>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-2001" MODIFIED="2008-11-21 10:10:06 +0000" MODIFIED_BY="[Empty name]" NAME="French 2001" TYPE="COCHRANE_REVIEW">
<AU>French L</AU>
<TI>Oral prostaglandin E2 for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:09:48 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:09:48 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003098"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2008-11-20 15:41:29 +0000" MODIFIED_BY="Lynn Hampson" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2000" MODIFIED="2008-06-09 11:08:01 +0100" MODIFIED_BY="Denise Atherton" NAME="Hofmeyr 2000" TYPE="COCHRANE_PROTOCOL">
<AU>Hofmeyr GJ, Alfirevic Z, Kelly T, Kavanagh J, Thomas J, Brocklehurst P, et al</AU>
<TI>Methods for cervical ripening and labour induction in late pregnancy: generic protocol</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-04-14 14:44:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-04-14 14:44:26 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002074"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hofmeyr-2003" MODIFIED="2008-11-21 09:51:01 +0000" MODIFIED_BY="[Empty name]" NAME="Hofmeyr 2003" TYPE="COCHRANE_REVIEW">
<AU>Hofmeyr GJ, Gülmezoglu AM</AU>
<TI>Vaginal misoprostol for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-11-21 09:51:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 09:51:01 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000941"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Howarth-2001" MODIFIED="2008-11-21 09:49:16 +0000" MODIFIED_BY="[Empty name]" NAME="Howarth 2001" TYPE="COCHRANE_REVIEW">
<AU>Howarth GR, Botha DJ</AU>
<TI>Amniotomy plus intravenous oxytocin for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-11-21 09:49:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 09:49:16 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003250"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2001" MODIFIED="2008-11-21 10:05:39 +0000" MODIFIED_BY="[Empty name]" NAME="Hutton 2001" TYPE="COCHRANE_REVIEW">
<AU>Hutton EK, Mozurkewich EL</AU>
<TI>Extra-amniotic prostaglandin for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:05:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:05:04 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003092"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2001" MODIFIED="2008-11-21 10:25:16 +0000" MODIFIED_BY="[Empty name]" NAME="Kavanagh 2001" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Sexual intercourse for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:25:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:25:16 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003093"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2005" MODIFIED="2008-11-21 10:23:06 +0000" MODIFIED_BY="[Empty name]" NAME="Kavanagh 2005" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Breast stimulation for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:22:49 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:22:49 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003392.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2006" MODIFIED="2008-11-21 10:15:41 +0000" MODIFIED_BY="[Empty name]" NAME="Kavanagh 2006" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Corticosteroids for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:15:21 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:15:21 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003100.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2006a" MODIFIED="2008-11-21 10:18:50 +0000" MODIFIED_BY="[Empty name]" NAME="Kavanagh 2006a" TYPE="COCHRANE_REVIEW">
<AU>Kavanagh J, Kelly AJ, Thomas J</AU>
<TI>Hyaluronidase for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:18:50 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:18:50 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003097.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2001" MODIFIED="2008-11-21 09:51:33 +0000" MODIFIED_BY="[Empty name]" NAME="Kelly 2001" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Tan BP</AU>
<TI>Intravenous oxytocin alone for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-11-21 09:45:08 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 09:45:08 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2001a" MODIFIED="2008-11-21 10:17:06 +0000" MODIFIED_BY="[Empty name]" NAME="Kelly 2001a" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Kavanagh J, Thomas J</AU>
<TI>Relaxin for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:16:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:16:47 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003103"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2001b" MODIFIED="2008-11-21 10:20:09 +0000" MODIFIED_BY="[Empty name]" NAME="Kelly 2001b" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Kavanagh J, Thomas J</AU>
<TI>Castor oil, bath and/or enema for cervical priming and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:19:48 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:19:48 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003099"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2003" MODIFIED="2008-11-21 09:51:55 +0000" MODIFIED_BY="[Empty name]" NAME="Kelly 2003" TYPE="COCHRANE_REVIEW">
<AU>Kelly AJ, Kavanagh J, Thomas J</AU>
<TI>Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-21 09:51:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 09:51:55 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003101"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2008" MODIFIED="2008-11-21 10:28:45 +0000" MODIFIED_BY="[Empty name]" NAME="Kelly 2008" TYPE="COCHRANE_PROTOCOL">
<AU>Kelly AJ, Kavanagh J</AU>
<TI>Nitric oxide donors for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:28:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:28:45 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006901"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Luckas-2000" MODIFIED="2008-11-21 10:07:39 +0000" MODIFIED_BY="[Empty name]" NAME="Luckas 2000" TYPE="COCHRANE_REVIEW">
<AU>Luckas M, Bricker L</AU>
<TI>Intravenous prostaglandin for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:07:14 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:07:14 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002864"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Muzonzini-2004" MODIFIED="2008-11-21 10:30:02 +0000" MODIFIED_BY="[Empty name]" NAME="Muzonzini 2004" TYPE="COCHRANE_REVIEW">
<AU>Muzonzini G, Hofmeyr GJ</AU>
<TI>Buccal or sublingual misoprostol for cervical ripening and induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:29:39 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:29:39 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004221.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neilson-2000" MODIFIED="2008-11-21 10:11:50 +0000" MODIFIED_BY="[Empty name]" NAME="Neilson 2000" TYPE="COCHRANE_REVIEW">
<AU>Neilson JP</AU>
<TI>Mifepristone for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:11:50 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:11:50 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002865"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2008-11-20 15:41:47 +0000" MODIFIED_BY="Lynn Hampson" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Copenhagen, The Nordic Cochrane Centre</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2003" MODIFIED="2008-11-21 10:26:31 +0000" MODIFIED_BY="[Empty name]" NAME="Smith 2003" TYPE="COCHRANE_REVIEW">
<AU>Smith CA</AU>
<TI>Homoeopathy for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:26:10 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:26:10 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003399"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smith-2004" MODIFIED="2008-11-21 10:21:47 +0000" MODIFIED_BY="[Empty name]" NAME="Smith 2004" TYPE="COCHRANE_REVIEW">
<AU>Smith CA, Crowther CA</AU>
<TI>Acupuncture for induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:21:25 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:21:25 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002962.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2001" MODIFIED="2008-11-21 10:13:34 +0000" MODIFIED_BY="[Empty name]" NAME="Thomas 2001" TYPE="COCHRANE_REVIEW">
<AU>Thomas J, Kelly AJ, Kavanagh J</AU>
<TI>Oestrogens alone or with amniotomy for cervical ripening or induction of labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-11-21 10:13:15 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-21 10:13:15 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003393"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2008-11-20 15:54:44 +0000" MODIFIED_BY="Lynn Hampson"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-07-27 15:37:39 +0100" MODIFIED_BY="Sonja L  Henderson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-07-27 15:37:39 +0100" MODIFIED_BY="Sonja L  Henderson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-07-24 16:28:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allouche-1993">
<CHAR_METHODS MODIFIED="2009-07-24 16:27:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 16:27:43 +0100" MODIFIED_BY="[Empty name]">
<P>Women presenting for non urgent induction of labour and a Bishop's score of &lt; 6. Excluded malpresenations multiple pregnancies, previous uterine scar, ruptured membranes acute fetal distress and women in labour.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:28:02 +0100" MODIFIED_BY="[Empty name]">
<P>1. 18 G. Foley with 50 cc balloon plus traction with normal saline;</P>
<P>2. 18 G. Foley with 50 cc balloon plus traction with extraamniotic prostaglandin E2 preceded by 0.01% (0.5 mg) salbutamol;</P>
<P>3. prostaglandin E2 intracervically preceded by 0.01% (0.5 mg) salbutamol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:28:14 +0100" MODIFIED_BY="[Empty name]">
<P>2, 3, 12, 20, 22.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>3 study groups; all included under separate comparisons as per Cochrane Handbook 16.5.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 16:29:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarke-1980">
<CHAR_METHODS MODIFIED="2009-07-24 16:28:47 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi randomised - allocation by date of birth.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 16:28:51 +0100" MODIFIED_BY="[Empty name]">
<P>Multiparous or nulliparous, requiring induction.<BR/>No information about multiple pregnancy inclusion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:29:10 +0100" MODIFIED_BY="[Empty name]">
<P>Vaginal PGE2 2.0 mgm (PGE2 - Upjohn) in 10 ml Tylose gel.<BR/>Extra-amniotic PGE2 gel 0.3 mgm in 10 ml 6% tylose gel.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:29:23 +0100" MODIFIED_BY="[Empty name]">
<P>1, 8, 12, 17 (see footnotes).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:29:34 +0100" MODIFIED_BY="[Empty name]">
<P>Catheter removed after insertion.<BR/>Oxytocin was initiated after 20 hours following ARM when indicated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 16:30:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fenton-1985">
<CHAR_METHODS MODIFIED="2009-07-24 16:30:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double blind trial.<BR/>Allocation unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 16:30:18 +0100" MODIFIED_BY="[Empty name]">
<P>Nulliparous, Bishop's score &lt; 4, &gt; 36 weeks.<BR/>No information available regarding inclusion of multiples.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:30:26 +0100" MODIFIED_BY="[Empty name]">
<P>Extra-amniotic:<BR/>- placebo gel;<BR/>- PGE2 gel 400 mgm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:30:30 +0100" MODIFIED_BY="[Empty name]">
<P>3.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:30:39 +0100" MODIFIED_BY="[Empty name]">
<P>Placebo and PGE2 inserted via catheter, which was then withdrawn.<BR/>Oxytocin started 'the following morning'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 16:31:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greer-1989">
<CHAR_METHODS MODIFIED="2009-07-24 16:30:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised - allocation unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>50 nulliparous,<BR/>Bishop's score &lt; 4, singleton pregnancy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:31:01 +0100" MODIFIED_BY="[Empty name]">
<P>Extra-amniotic PGE2 (500 microgram).<BR/>Vaginal PGE2 3 mg tablets x 2 in posterior fornix.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:31:08 +0100" MODIFIED_BY="[Empty name]">
<P>3, 10, 11, 12.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:31:19 +0100" MODIFIED_BY="[Empty name]">
<P>Catheter inflated to 20 ml, left in situ.</P>
<P>Timing of oxytocin augmentation not known.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 16:32:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahomed-1988">
<CHAR_METHODS MODIFIED="2009-07-24 16:31:49 +0100" MODIFIED_BY="[Empty name]">
<P>RCT - allocation by computer generated sequence.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>77 singleton, live vertex, Bishop's score &lt; 6, admitted for induction.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:31:58 +0100" MODIFIED_BY="[Empty name]">
<P>2.5 mg PGF2alpha in 20 ml Tylose gel via Foley catheter.<BR/>Foley catheter with traction.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:32:08 +0100" MODIFIED_BY="[Empty name]">
<P>2, 3, 4, 7, 10, 13, 15</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:32:16 +0100" MODIFIED_BY="[Empty name]">
<P>Catheter inflated to 30 ml, left in situ.<BR/>Oxytocin and amniotomy 16 hours following treatment with PGF2alpha.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-27 15:13:09 +0100" MODIFIED_BY="Sonja L  Henderson" STUDY_ID="STD-Majoko-2002a">
<CHAR_METHODS MODIFIED="2009-07-24 16:32:27 +0100" MODIFIED_BY="[Empty name]">
<P>RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 16:32:35 +0100" MODIFIED_BY="[Empty name]">
<P>Women with singleton cephalic fetus at &gt; 36 weeks' gestation. Women with prior uterine surgery, an abnormal FHR, any contraindication to vaginal delivery or a know sensitivity to PGF2alpha or misoprostol were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 15:13:09 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Intervention group: PGF2alpha prepared by hospital pharmacy in 5 mg mixed in 20 ml Tylose gel inserted via 22 G Goley inflated to 40 ml and left in situ. Repeat dose q8 x 1 dose for women with catheter still in place.</P>
<P>Control group: misoprostol 50microgram (divided from 200 microgram tablet) inserted into the posterior vaginal fornix and repeated q8h if Bishop's score &lt; 10.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:33:34 +0100" MODIFIED_BY="[Empty name]">
<P>1, 3, 5, 7, 9, 12, 14, 16, 23. Other: fetal distress necessitating caesarean; Apgar &lt; 5 (time not known).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:33:40 +0100" MODIFIED_BY="[Empty name]">
<P>It is unclear if the data reported in this paper are duplicate data from the publication in the Central Arfican Journal of Medicine. Attempts have been made to contact the author in order to clarify. If there is no duplication, the data from the second paper will be added.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 16:34:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parewicjk-1986">
<CHAR_METHODS MODIFIED="2009-07-24 16:33:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial - allocation unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>194 nulliparous or multiparous, 'clinically normal', Bishop's score &lt; 6, clinically normal.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:34:05 +0100" MODIFIED_BY="[Empty name]">
<P>Extra-amniotic 500 micrograms PGE2 in 8 ml Tylose gel.<BR/>Intracervical 0.5 mg. PGE2 l in 2.5 ml triacetine gel.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:34:06 +0100" MODIFIED_BY="[Empty name]">
<P>3.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:34:10 +0100" MODIFIED_BY="[Empty name]">
<P>No information on catheter.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 16:34:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quinn-1981">
<CHAR_METHODS MODIFIED="2009-07-24 16:34:17 +0100" MODIFIED_BY="[Empty name]">
<P>Double blind trial - allocation unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 16:34:26 +0100" MODIFIED_BY="[Empty name]">
<P>40 nulliparous, modified Bishop's score &lt; 4.<BR/>Unknown if multiple pregnancy included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:34:34 +0100" MODIFIED_BY="[Empty name]">
<P>Extra-amniotic:<BR/>- placebo gel;<BR/>- 10 mg PGF2alpha in Tylose gel;<BR/>- 15 mg oestriol in tylose gel.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:34:39 +0100" MODIFIED_BY="[Empty name]">
<P>3, 8, 10, 15.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:34:54 +0100" MODIFIED_BY="[Empty name]">
<P>Oxytocin augmentation initiated 12 hours following treatment.<BR/>All gel via Foley catheter inflated to 10 ml, left in place.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 16:35:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shepherd-1976">
<CHAR_METHODS MODIFIED="2009-07-24 16:35:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised - allocation by alternation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 16:35:08 +0100" MODIFIED_BY="[Empty name]">
<P>30 nulliparous or multiparous Bishop's score &lt; 4, &gt; 36 weeks.<BR/>No information regarding singleton vs multiple or VBAC pregnancy included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:35:13 +0100" MODIFIED_BY="[Empty name]">
<P>Extra-amniotic:<BR/>- placebo gel;<BR/>- PGE2 250 microgram in Tylose gel.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:35:20 +0100" MODIFIED_BY="[Empty name]">
<P>2, 3, 7, 8, 10, 17.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>All gel via catheter, no information re: catheter left in place or removed.<BR/>Oxytocin induction initiated 14.5 hours following treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 16:53:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sherman-2001">
<CHAR_METHODS MODIFIED="2009-07-24 16:53:35 +0100" MODIFIED_BY="[Empty name]">
<P>Double blinded RCT comparing balloon cervical ripening of the cervix with extra-amniotic infusion of saline vs PGE2alpha.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 16:53:40 +0100" MODIFIED_BY="[Empty name]">
<P>Women with singleton cephalic live fetuses and intact membranes with a Bishop's score &lt; 4 were included; women with prior uterine surgery, vaginal bleeding an estimated fetal weight of &gt; 4300 g, vaginal infection, low lying placenta or who were in labour or had urgent need of delivery were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:53:47 +0100" MODIFIED_BY="[Empty name]">
<P>All women had a 22 G Foley balloon catheter placed with 30 ml of sterile water inflating the balloon. In the intervention group, an infusion pump was used to deliver PGE2 solution (10 mg/ml saline) at a rate of 1 ml/min. In the control group, normal saline was infused at the same rate.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:36:29 +0100" MODIFIED_BY="[Empty name]">
<P>3, 7, 13, 18. Other: intrapartum fever, abnormal FHR, dystocia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:53:49 +0100" MODIFIED_BY="[Empty name]">
<P>This is a study of cervical ripening as opposed to induction, but as many women go on to labour spontaneously with this management it is included. The oxytocin induction outcome was added to the oxytocin augmentation outcome.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 16:37:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stewart-1985">
<CHAR_METHODS MODIFIED="2009-07-24 16:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>RCT - allocation unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>62 nulliparous, Bishop's score &lt; 4, singleton pregnancy, cephalic presentation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:36:54 +0100" MODIFIED_BY="[Empty name]">
<P>450 microgram extra-amniotic PGE2 in Tylose gel.<BR/>Vaginal PGE2 3 mg tablet.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:37:05 +0100" MODIFIED_BY="[Empty name]">
<P>3, 5, 6, 7, 10, 12.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:37:16 +0100" MODIFIED_BY="[Empty name]">
<P>Catheter inflated to 20 ml and left in situ.<BR/>Amniotomy performed when labour established.<BR/>Oxytocin 18 hours folowing extra-amniotic PGE2.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-24 16:37:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilson-1978">
<CHAR_METHODS MODIFIED="2009-07-24 16:37:27 +0100" MODIFIED_BY="[Empty name]">
<P>RCT - allocation unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 16:37:31 +0100" MODIFIED_BY="[Empty name]">
<P>60 nulliparous Bishop's score &lt; 5, with OB indication for induction.<BR/>No information about multiple pregnancy inclusion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-24 16:37:45 +0100" MODIFIED_BY="[Empty name]">
<P>Extra-amniotic 400 micrograms PGE2 gel.<BR/>IV oxytocin.<BR/>Vaginal PGE2 tablets 2 mg in posterior fornex.<BR/>Oral PGE2 of 1mg hourly for 10 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:37:48 +0100" MODIFIED_BY="[Empty name]">
<P>3, 10.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 16:37:51 +0100" MODIFIED_BY="[Empty name]">
<P>No information on Foley.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Outcomes:<BR/>1: vaginal delivery not achieved in 24 hours<BR/>2: uterine hyperstimulatin with fetal heart rate changes<BR/>3: caesarean section<BR/>4: serious neonatal morbidity/perinatal death<BR/>5: maternal satisfaction<BR/>6: maternal satisfaction, embarrassment<BR/>7: oxytocin augmentation<BR/>8: uterine hyperstimulation without fetal heart rate changes<BR/>10: instrumental vaginal delivery<BR/>11: meconium stained liquor<BR/>12: Apgar score &lt; 7 at 5 minutes<BR/>13: neonatal intensive care unit admission<BR/>15: perinatal death<BR/>17: maternal side-effects (nausea, fever, vomiting, diarrhoea)<BR/>21: women not satisfied<BR/>23: woman embarrassed<BR/>ARM: artificial rupture of membranes<BR/>IV: intravenous<BR/>OB: obstetric<BR/>RCT: randomised controlled trial<BR/>VBAC: vaginal birth after caesarean section<BR/>vs: versus<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-07-24 16:39:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Calder-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Neonatal studies with incompatible outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 16:39:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fletcher-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 16:39:15 +0100" MODIFIED_BY="[Empty name]">
<P>No relevant outcomes available in abstract.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Keirse-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Incomparable outcome - plasma levels of prostaglandin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reichel-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Incomparable outcome - plasma levels of prostaglandin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salamalekis-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Entry criterion intrauterine fetal death.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thiery-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>No primary outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thoumsin-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>No primary outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Toppozada-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Entry criterion intrauterine fetal death.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tsalacopoulo-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Entry criterion intrauterine fetal death.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-07-27 15:13:19 +0100" MODIFIED_BY="Sonja L  Henderson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-07-27 15:13:19 +0100" MODIFIED_BY="Sonja L  Henderson" STUDY_ID="STD-Majoko-2002b">
<CHAR_METHODS MODIFIED="2009-07-24 16:39:32 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial with 4 intervention arms.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-24 16:39:36 +0100" MODIFIED_BY="[Empty name]">
<P>Women with singleton cephalic fetus at &gt; 36 weeks' gestation. Women with prior uterine surgery, an abnormal FHR, any contraindication to vaginal delivery or a know sensitivity to PGF2alpha or misoprostol were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-27 15:13:19 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>4 group study: intervention group: PGF2alpha prepared by hospital pharmacy in 5 mg mixed in 20 ml Tylose gel inserted via 22 G Foley inflated to 40 ml and left in situ. Repeat dose q8 x 1 dose for women with catheter still in place.</P>
<P>Control groups:1. misoprostol 50 microgram (divided from 200 microgram tablet) inserted into the posterior vaginal fornix and repeated q8h if Bishop's score &lt; 10 (n = 128);</P>
<P>2. oral misoprostol (n = 127);</P>
<P>3. PGE2 pessary (n = 75).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-24 16:41:08 +0100" MODIFIED_BY="[Empty name]">
<P>1, 3, 5, 7, 9, 12, 14, 16, 23. Other: fetal distress necessitating caesarean; Apgar &lt; 5 (time not known).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-24 11:20:42 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Although it appears likely, it is unclear if the data reported in this paper are duplicate data from the publication in the International Journal of Obstetrics and Gynecology. Attempts have been made to contact the author in order to clarify. If there is no duplication, the data from this second paper will be added.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>FHR: fetal heart rate</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-08-05 19:45:17 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-07-27 15:37:39 +0100" MODIFIED_BY="Sonja L  Henderson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-07-27 15:37:39 +0100" MODIFIED_BY="Sonja L  Henderson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-24 16:28:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allouche-1993">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:36:50 +0100" MODIFIED_BY="Sonja L  Henderson" RESULT="NO" STUDY_ID="STD-Clarke-1980">
<DESCRIPTION>
<P>Inadequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:36:56 +0100" MODIFIED_BY="Sonja L  Henderson" RESULT="YES" STUDY_ID="STD-Fenton-1985">
<DESCRIPTION>
<P>Adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:37:01 +0100" MODIFIED_BY="Sonja L  Henderson" RESULT="UNKNOWN" STUDY_ID="STD-Greer-1989">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:37:06 +0100" MODIFIED_BY="Sonja L  Henderson" RESULT="YES" STUDY_ID="STD-Mahomed-1988">
<DESCRIPTION>
<P>Adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-24 16:33:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Majoko-2002a">
<DESCRIPTION>
<P>Sealed opaque sequentially numbered envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:37:15 +0100" MODIFIED_BY="Sonja L  Henderson" RESULT="UNKNOWN" STUDY_ID="STD-Parewicjk-1986">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:37:20 +0100" MODIFIED_BY="Sonja L  Henderson" RESULT="UNKNOWN" STUDY_ID="STD-Quinn-1981">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:37:25 +0100" MODIFIED_BY="Sonja L  Henderson" RESULT="UNKNOWN" STUDY_ID="STD-Shepherd-1976">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-24 16:36:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sherman-2001">
<DESCRIPTION>
<P>Computer-generated sequence; sealed opaque sequentially numbered envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:37:33 +0100" MODIFIED_BY="Sonja L  Henderson" RESULT="UNKNOWN" STUDY_ID="STD-Stewart-1985">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-27 15:37:39 +0100" MODIFIED_BY="Sonja L  Henderson" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1978">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-04-14 14:26:09 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-07-31 15:19:54 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-31 15:19:54 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Extra-amniotic PGE2 vs extra-amniotic placebo: all women</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 12:54:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-05 22:25:07 +0100" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.0" STUDY_ID="STD-Sherman-2001" TOTAL_1="58" TOTAL_2="58" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 12:54:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>EX placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6304" O_E="0.0" SE="0.0" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4003976824203702" CI_END="1.1988222565530642" CI_START="0.2639309107504835" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.07875479717689043" LOG_CI_START="-0.5785097436100901" LOG_EFFECT_SIZE="-0.24987747321659987" METHOD="MH" MODIFIED="2009-07-31 12:55:00 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.818568047192277" P_Q="0.0" P_Z="0.1361532297025176" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="88" WEIGHT="100.0" Z="1.4902701048378508">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7491265621242627" CI_START="0.09147422688823888" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.24282123500387298" LOG_CI_START="-1.038701252347948" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="6305" O_E="0.0" SE="0.752772652709081" STUDY_ID="STD-Fenton-1985" TOTAL_1="15" TOTAL_2="15" VAR="0.5666666666666667" WEIGHT="31.25"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="6306" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="6.25"/>
<DICH_DATA CI_END="1.5427895050612546" CI_START="0.2333435629546278" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.18830667588399147" LOG_CI_START="-0.6320041751167044" LOG_EFFECT_SIZE="-0.22184874961635637" MODIFIED="2008-08-05 22:16:24 +0100" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.48185465448200976" STUDY_ID="STD-Sherman-2001" TOTAL_1="58" TOTAL_2="58" VAR="0.232183908045977" WEIGHT="62.5"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6028202623619472" CI_START="0.18024868838023178" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.20488482401294653" LOG_CI_START="-0.7441278868376607" LOG_EFFECT_SIZE="-0.26962153141235706" METHOD="MH" MODIFIED="2009-07-31 15:19:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.2654162813494769" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="53" WEIGHT="100.0" Z="1.1136805334274236">
<NAME>Abnormal FHR</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6028202623619467" CI_START="0.18024868838023184" EFFECT_SIZE="0.5375" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.20488482401294641" LOG_CI_START="-0.7441278868376606" LOG_EFFECT_SIZE="-0.26962153141235706" MODIFIED="2008-08-05 22:27:58 +0100" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.5574547640423286" STUDY_ID="STD-Sherman-2001" TOTAL_1="54" TOTAL_2="53" VAR="0.31075581395348834" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8660288767639168" CI_START="0.35550204447092315" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8144796380090498" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.2709183601619215" LOG_CI_START="-0.4491578973255308" LOG_EFFECT_SIZE="-0.08911976858180463" METHOD="MH" MODIFIED="2009-07-31 12:55:42 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.6275718424237865" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="53" WEIGHT="100.0" Z="0.4851473296463329">
<NAME>Dystocia</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8660288767639168" CI_START="0.35550204447092315" EFFECT_SIZE="0.8144796380090498" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.2709183601619215" LOG_CI_START="-0.4491578973255308" LOG_EFFECT_SIZE="-0.08911976858180463" MODIFIED="2008-08-05 22:27:02 +0100" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.42297635808309053" STUDY_ID="STD-Sherman-2001" TOTAL_1="54" TOTAL_2="53" VAR="0.17890899949723482" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.198626539467563" CI_START="0.34296929876087756" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.6231072466166075" LOG_CI_START="-0.46474475452135783" LOG_EFFECT_SIZE="0.07918124604762482" METHOD="MH" MODIFIED="2009-07-31 12:55:56 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.7753998031717235" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="53" WEIGHT="100.0" Z="0.2853189410728805">
<NAME>Intrapartum fever</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.198626539467562" CI_START="0.34296929876087767" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.6231072466166074" LOG_CI_START="-0.46474475452135766" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2008-10-30 18:27:25 +0000" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.6390096504226938" STUDY_ID="STD-Sherman-2001" TOTAL_1="54" TOTAL_2="53" VAR="0.4083333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.01366454752893587" CI_END="0.6735342449908752" CI_START="0.3855322792444351" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5095774647887324" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.17164031822981643" LOG_CI_START="-0.4139392541607441" LOG_EFFECT_SIZE="-0.2927897861952803" METHOD="MH" MODIFIED="2009-07-31 12:56:06 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9931910132438447" P_Q="0.0" P_Z="2.1714898052701714E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="83" WEIGHT="100.0" Z="4.736772233680153">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8732829682233898" CI_START="0.2862760515169567" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="-0.05884500987327864" LOG_CI_START="-0.5432149814546838" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="6308" O_E="0.0" SE="0.28452131897694577" STUDY_ID="STD-Fenton-1985" TOTAL_1="15" TOTAL_2="15" VAR="0.08095238095238093" WEIGHT="21.098591549295776"/>
<DICH_DATA CI_END="0.8732829682233898" CI_START="0.2862760515169567" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="-0.05884500987327864" LOG_CI_START="-0.5432149814546838" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="6309" O_E="0.0" SE="0.28452131897694577" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.08095238095238093" WEIGHT="21.098591549295776"/>
<DICH_DATA CI_END="0.7604576081062576" CI_START="0.3508989013322099" EFFECT_SIZE="0.5165692007797271" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="38" LOG_CI_END="-0.1189249907874074" LOG_CI_START="-0.4548179915626094" LOG_EFFECT_SIZE="-0.2868714911750084" MODIFIED="2008-08-05 22:18:45 +0100" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.1973052113525231" STUDY_ID="STD-Sherman-2001" TOTAL_1="54" TOTAL_2="53" VAR="0.03892934642686381" WEIGHT="57.802816901408455"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="132.56091895285982" CI_START="0.3696413723370833" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="2.122415506083978" LOG_CI_START="-0.43221942605546465" LOG_EFFECT_SIZE="0.8450980400142568" METHOD="MH" MODIFIED="2009-07-31 14:42:45 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.19471713925414433" Q="0.0" RANDOM="NO" SCALE="185.32" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="73" WEIGHT="100.0" Z="1.29675023307238">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6311" O_E="0.0" SE="0.0" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="132.56091895285982" CI_START="0.3696413723370833" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.122415506083978" LOG_CI_START="-0.43221942605546465" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2008-10-30 18:08:43 +0000" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="1.5006052047855691" STUDY_ID="STD-Sherman-2001" TOTAL_1="58" TOTAL_2="58" VAR="2.25181598062954" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="38.98015494341516" CI_START="0.4573393953847961" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="1.590843561075509" LOG_CI_START="-0.33976138672053846" LOG_EFFECT_SIZE="0.6255410871774852" METHOD="MH" MODIFIED="2009-07-31 14:43:03 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.2040463325822195" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="58" WEIGHT="100.0" Z="1.2701075930811532">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic saline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="38.98015494341516" CI_START="0.4573393953847961" EFFECT_SIZE="4.222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.590843561075509" LOG_CI_START="-0.33976138672053846" LOG_EFFECT_SIZE="0.6255410871774852" MODIFIED="2008-10-31 18:29:45 +0000" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="1.1340469029840174" STUDY_ID="STD-Sherman-2001" TOTAL_1="58" TOTAL_2="58" VAR="1.2860623781676415" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3452615705961373" CI_START="0.5569197335406777" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.3701912872777029" LOG_CI_START="-0.2542073933223293" LOG_EFFECT_SIZE="0.05799194697768673" METHOD="MH" MODIFIED="2009-07-31 14:43:14 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.7158064239433395" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.3640690827866448">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3452615705961373" CI_START="0.5569197335406775" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3701912872777029" LOG_CI_START="-0.25420739332232944" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="6313" O_E="0.0" SE="0.36677487580777607" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.13452380952380955" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8216007164370154" CI_END="4.227889409751237" CI_START="0.548139688186746" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5223251895534962" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.6261236188049875" LOG_CI_START="-0.2611087515923062" LOG_EFFECT_SIZE="0.1825074336063406" METHOD="MH" MODIFIED="2009-07-31 14:43:24 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.364712632132841" P_Q="0.0" P_Z="0.4200435627824103" Q="0.0" RANDOM="NO" SCALE="291.06" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="84" TOTAL_2="83" WEIGHT="100.0" Z="0.8063456851085916">
<NAME>Maternal side-effects</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-31 12:15:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>GI side-effects (nausea and vomiting or diarrhea)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6314" O_E="0.0" SE="0.0" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8216007164370154" CI_END="4.227889409751237" CI_START="0.548139688186746" DF="1.0" EFFECT_SIZE="1.5223251895534962" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.6261236188049875" LOG_CI_START="-0.2611087515923062" LOG_EFFECT_SIZE="0.1825074336063406" MODIFIED="2009-07-31 12:41:44 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.364712632132841" P_Z="0.4200435627824103" STUDIES="2" TAU2="0.0" TOTAL_1="69" TOTAL_2="68" WEIGHT="100.0" Z="0.8063456851085916">
<NAME>Non-GI side-effects (non-shivering)</NAME>
<DICH_DATA CI_END="96.12715085961011" CI_START="0.260072204121721" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="6315" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="9.014321819713563"/>
<DICH_DATA CI_END="3.6266684882193463" CI_START="0.38248891464249624" EFFECT_SIZE="1.1777777777777778" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5595078587739541" LOG_CI_START="-0.41738114712306346" LOG_EFFECT_SIZE="0.07106335582544539" MODIFIED="2008-08-05 22:22:16 +0100" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.5738294377424762" STUDY_ID="STD-Sherman-2001" TOTAL_1="54" TOTAL_2="53" VAR="0.3292802236198463" WEIGHT="90.98567818028644"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-07-31 14:54:28 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Extra-amniotic PGE2 vs extra-amniotic placebo: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 14:45:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6316" O_E="0.0" SE="0.0" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.34525562168773094" CI_END="1.7767972782564796" CI_START="0.14070260184398634" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.24963788027753067" LOG_CI_START="-0.8516978716054929" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2009-07-31 14:46:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5568113646128146" P_Q="0.0" P_Z="0.28397135712786503" Q="0.0" RANDOM="NO" SCALE="34.09" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.00000000000001" Z="1.0714406551478561">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7491265621242627" CI_START="0.09147422688823888" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.24282123500387298" LOG_CI_START="-1.038701252347948" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="6317" O_E="0.0" SE="0.752772652709081" STUDY_ID="STD-Fenton-1985" TOTAL_1="15" TOTAL_2="15" VAR="0.5666666666666667" WEIGHT="83.33333333333334"/>
<DICH_DATA CI_END="14.553341064518706" CI_START="0.06871274407483083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1629627073641946" LOG_CI_START="-1.1629627073641946" LOG_EFFECT_SIZE="0.0" ORDER="6318" O_E="0.0" SE="1.3662601021279464" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="1.8666666666666667" WEIGHT="16.666666666666668"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7416869712333676" CI_START="0.33706942375470006" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.12977934990980775" LOG_CI_START="-0.4722806414181546" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2009-07-31 14:46:21 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="5.704493353903883E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="3.4452889048640163">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8732829682233898" CI_START="0.2862760515169567" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="-0.05884500987327864" LOG_CI_START="-0.5432149814546838" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="6320" O_E="0.0" SE="0.28452131897694577" STUDY_ID="STD-Fenton-1985" TOTAL_1="15" TOTAL_2="15" VAR="0.08095238095238093" WEIGHT="50.0"/>
<DICH_DATA CI_END="0.8732829682233898" CI_START="0.2862760515169567" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="-0.05884500987327864" LOG_CI_START="-0.5432149814546838" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="6321" O_E="0.0" SE="0.28452131897694577" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.08095238095238093" WEIGHT="50.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 14:46:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="243.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6323" O_E="0.0" SE="0.0" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3452615705961373" CI_START="0.5569197335406777" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.3701912872777029" LOG_CI_START="-0.2542073933223293" LOG_EFFECT_SIZE="0.05799194697768673" METHOD="MH" MODIFIED="2009-07-31 14:46:35 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.7158064239433395" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.3640690827866448">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3452615705961373" CI_START="0.5569197335406775" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3701912872777029" LOG_CI_START="-0.25420739332232944" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="6325" O_E="0.0" SE="0.36677487580777607" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.13452380952380955" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="96.12715085961011" CI_START="0.260072204121721" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" MODIFIED="2009-07-31 14:46:45 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.28595065344202353" Q="0.0" RANDOM="NO" SCALE="382.29" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.067046945624763">
<NAME>Maternal side-effects</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-31 12:15:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>GI side-effects (nausea and vomiting or diarrhea)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6326" O_E="0.0" SE="0.0" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="96.12715085961011" CI_START="0.260072204121721" DF="0.0" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-07-31 12:15:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.28595065344202353" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.067046945624763">
<NAME>Non-GI side-effects (non-shivering)</NAME>
<DICH_DATA CI_END="96.12715085961011" CI_START="0.260072204121721" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.982846070323241" LOG_CI_START="-0.5849060616512035" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="6327" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Shepherd-1976" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-07-31 14:47:59 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Extra-amniotic PGE2 vs extra-amniotic placebo: all primiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7491265621242627" CI_START="0.09147422688823888" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.24282123500387298" LOG_CI_START="-1.038701252347948" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" MODIFIED="2009-07-31 14:47:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.2235201392776368" Q="0.0" RANDOM="NO" SCALE="16.96" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.21722106744527">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7491265621242627" CI_START="0.09147422688823888" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.24282123500387298" LOG_CI_START="-1.038701252347948" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="6328" O_E="0.0" SE="0.752772652709081" STUDY_ID="STD-Fenton-1985" TOTAL_1="15" TOTAL_2="15" VAR="0.5666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8732829682233898" CI_START="0.2862760515169567" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-0.05884500987327864" LOG_CI_START="-0.5432149814546838" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2009-07-31 14:47:25 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.014843002900393192" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="2.43618714777612">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8732829682233898" CI_START="0.2862760515169567" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="-0.05884500987327864" LOG_CI_START="-0.5432149814546838" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="6329" O_E="0.0" SE="0.28452131897694577" STUDY_ID="STD-Fenton-1985" TOTAL_1="15" TOTAL_2="15" VAR="0.08095238095238093" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-07-31 14:48:56 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Extra-amniotic PGF2 alpha vs extra-amniotic placebo gel: all women</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2045099580700085" CI_START="0.03467335491696534" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.5057616254997814" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" MODIFIED="2009-07-31 14:48:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.34138810212716" Q="0.0" RANDOM="NO" SCALE="75.79" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.951426150896346">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.204509958070007" CI_START="0.03467335491696534" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5057616254997813" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="6330" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="1.3333333333333333" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:48:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="140.7" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6331" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:48:38 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="196.11" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6332" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1986320720361552" CI_START="0.2724193852832669" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" METHOD="MH" MODIFIED="2009-07-31 14:48:50 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.13871207429144086" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="1.480604204622589">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1986320720361552" CI_START="0.27241938528326687" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="6333" O_E="0.0" SE="0.37796447300922725" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.14285714285714288" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:48:56 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="310.38" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>PGF2A</GROUP_LABEL_1>
<GROUP_LABEL_2>PG placebo gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6334" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2009-07-31 14:54:19 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Extra-amniotic PGF2 alpha vs extra-amniotic placebo gel: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2045099580700085" CI_START="0.03467335491696534" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.5057616254997814" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" MODIFIED="2009-07-31 14:52:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.34138810212716" Q="0.0" RANDOM="NO" SCALE="64.9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.951426150896346">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.204509958070007" CI_START="0.03467335491696534" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5057616254997813" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="6335" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="1.3333333333333333" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:52:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="158.9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6336" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:52:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6337" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1986320720361552" CI_START="0.2724193852832669" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" METHOD="MH" MODIFIED="2009-07-31 14:52:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.13871207429144086" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="1.480604204622589">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1986320720361552" CI_START="0.27241938528326687" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="6338" O_E="0.0" SE="0.37796447300922725" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.14285714285714288" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:52:55 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="144.17" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>PGF2A</GROUP_LABEL_1>
<GROUP_LABEL_2>PG placebo gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6339" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2009-07-31 14:53:58 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Extra-amniotoc PGF2 alpha vs extra-amniotic placebo gel: all primiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2045099580700085" CI_START="0.03467335491696534" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.5057616254997814" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" MODIFIED="2009-07-31 14:53:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.34138810212716" Q="0.0" RANDOM="NO" SCALE="61.3" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.951426150896346">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.204509958070007" CI_START="0.03467335491696534" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5057616254997813" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="6340" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="1.3333333333333333" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:53:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="164.13" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6341" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:53:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="158.9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6342" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1986320720361552" CI_START="0.2724193852832669" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" METHOD="MH" MODIFIED="2009-07-31 14:53:49 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.13871207429144086" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="1.480604204622589">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1986320720361552" CI_START="0.27241938528326687" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="6343" O_E="0.0" SE="0.37796447300922725" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.14285714285714288" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:53:58 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="96.79" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>PGF2A</GROUP_LABEL_1>
<GROUP_LABEL_2>PG placebo gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6344" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2009-07-31 14:57:01 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Extra-amniotic PGF2 alpha vs placebo gel: all primiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2045099580700085" CI_START="0.03467335491696534" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.5057616254997814" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" MODIFIED="2009-07-31 14:56:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.34138810212716" Q="0.0" RANDOM="NO" SCALE="73.36" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.951426150896346">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.204509958070007" CI_START="0.03467335491696534" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5057616254997813" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="6345" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="1.3333333333333333" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:56:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="243.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6346" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:56:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="517.82" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6347" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1986320720361552" CI_START="0.2724193852832669" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-007.04" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" METHOD="MH" MODIFIED="2009-07-31 14:56:53 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.13871207429144086" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="1.480604204622589">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Extra-amniotic placebo gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1986320720361552" CI_START="0.27241938528326687" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.07868589401954948" LOG_CI_START="-0.5647619913921385" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="6348" O_E="0.0" SE="0.37796447300922725" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="0.14285714285714288" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="46.11324022630343" CI_START="0.09224912908144614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-007.05" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" METHOD="MH" MODIFIED="2009-07-31 14:57:01 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.6479317695865698" Q="0.0" RANDOM="NO" SCALE="173.7" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.0" Z="0.45663729486577115">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>PGF2A</GROUP_LABEL_1>
<GROUP_LABEL_2>PG placebo gel</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="46.11324022630343" CI_START="0.09224912908144614" EFFECT_SIZE="2.0625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6638256397419067" LOG_CI_START="-1.0350377252979814" LOG_EFFECT_SIZE="0.31439395722196267" ORDER="6349" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Quinn-1981" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2009-07-31 14:58:22 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Extra-amniotic PGE2 vs vaginal PGE2: all women</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5857931591074346" CI_START="1.0045936329250658" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2621718230001233" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.2002465400330103" LOG_CI_START="0.0019904212909079644" LOG_EFFECT_SIZE="0.10111848066195914" METHOD="MH" MODIFIED="2009-07-31 14:57:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.045573884883849794" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="128" WEIGHT="100.0" Z="1.9993186745137457">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5857931591074346" CI_START="1.0045936329250658" EFFECT_SIZE="1.2621718230001233" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="61" LOG_CI_END="0.2002465400330103" LOG_CI_START="0.0019904212909079644" LOG_EFFECT_SIZE="0.10111848066195914" ORDER="6350" O_E="0.0" SE="0.11645662553272622" STUDY_ID="STD-Clarke-1980" TOTAL_1="133" TOTAL_2="128" VAR="0.013562145630469619" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 14:57:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="128" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6351" O_E="0.0" SE="0.0" STUDY_ID="STD-Clarke-1980" TOTAL_1="133" TOTAL_2="128" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1229315106516997" CI_END="1.8895370865463788" CI_START="0.42037843978862205" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8912466843501328" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.27635542037284305" LOG_CI_START="-0.3763595660047406" LOG_EFFECT_SIZE="-0.05000207281594874" METHOD="MH" MODIFIED="2009-07-31 14:57:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5703725733656868" P_Q="0.0" P_Z="0.7639550954587279" Q="0.0" RANDOM="NO" SCALE="34.09" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="70" WEIGHT="100.0" Z="0.3002911344674299">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.1178990744020965" CI_START="0.37944106248569703" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6146756982879912" LOG_CI_START="-0.42085567227187837" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="6352" O_E="0.0" SE="0.608276253029822" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.37000000000000005" WEIGHT="32.891246684350136"/>
<DICH_DATA CI_END="2.917064814565508" CI_START="0.30129815615047" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4649460788630513" LOG_CI_START="-0.5210035260635382" LOG_EFFECT_SIZE="-0.02802872360024354" ORDER="6353" O_E="0.0" SE="0.5791516784631352" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="0.3354166666666667" WEIGHT="42.44031830238727"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="6354" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="24.668435013262602"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.299548383635253" CI_START="3.5004516163647454" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.3999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.04" MODIFIED="2009-07-31 14:57:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="9.080931447230152E-22" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="9.586856792655864">
<NAME>Maternal satisfaction</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.299548383635253" CI_START="3.5004516163647454" DF="0.0" EFFECT_SIZE="4.3999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-008.04.01" MODIFIED="2009-07-31 12:40:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="9.080931447230152E-22" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="9.586856792655864">
<NAME>Assessment of discomfort</NAME>
<CONT_DATA CI_END="5.299548383635253" CI_START="3.5004516163647454" EFFECT_SIZE="4.3999999999999995" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="1.2" ORDER="6355" SD_1="1.7" SD_2="1.9" SE="0.4589616904855277" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.5967926233681147" CI_END="1.3970809398018247" CI_START="0.7487821700116444" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0227948463825567" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="32" I2="37.37446019191271" I2_Q="0.0" ID="CMP-008.05" LOG_CI_END="0.1452215676682428" LOG_CI_START="-0.12564450555967896" LOG_EFFECT_SIZE="0.0097885310542819" METHOD="MH" MODIFIED="2009-07-31 14:57:45 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.2063583862321665" P_Q="0.0" P_Z="0.8873501793145505" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="55" WEIGHT="100.0" Z="0.14165796475958764">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3436827657608257" CI_START="0.4763029014795889" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.12829674688603437" LOG_CI_START="-0.32211677290214713" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="6356" O_E="0.0" SE="0.264575131106459" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.06999999999999998" WEIGHT="46.08523290386521"/>
<DICH_DATA CI_END="1.7928110041592065" CI_START="0.821023451706804" EFFECT_SIZE="1.213235294117647" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.2535345092069215" LOG_CI_START="-0.08564443751954406" LOG_EFFECT_SIZE="0.08394503584368873" ORDER="6357" O_E="0.0" SE="0.1992353922699901" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="0.03969474153297683" WEIGHT="53.91476709613478"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 14:57:51 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="128" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6358" O_E="0.0" SE="0.0" STUDY_ID="STD-Clarke-1980" TOTAL_1="133" TOTAL_2="128" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.363369663078036" CI_END="1.5526440007665367" CI_START="0.603846177618648" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9682758620689655" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-008.07" LOG_CI_END="0.19107188958170207" LOG_CI_START="-0.21907367846407888" LOG_EFFECT_SIZE="-0.01400089444118841" METHOD="MH" MODIFIED="2009-07-31 14:57:57 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8338641494348781" P_Q="0.0" P_Z="0.8935510471406517" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="70" WEIGHT="99.99999999999999" Z="0.133812241282165">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.243672097930701" CI_START="0.445697925700588" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.35095938713636066" LOG_CI_START="-0.35095938713636066" LOG_EFFECT_SIZE="0.0" ORDER="6359" O_E="0.0" SE="0.412310562561766" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.16999999999999998" WEIGHT="34.206896551724135"/>
<DICH_DATA CI_END="1.6445857530644812" CI_START="0.44906468954194073" EFFECT_SIZE="0.859375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.21605652367561667" LOG_CI_START="-0.34769109265490333" LOG_EFFECT_SIZE="-0.06581728448964332" ORDER="6360" O_E="0.0" SE="0.33114814042825447" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="0.10965909090909093" WEIGHT="52.9655172413793"/>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="6361" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="12.827586206896552"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.220339253228541" CI_START="0.2737113312101215" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-008.08" LOG_CI_END="0.9148897412340661" LOG_CI_START="-0.5627072231227036" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2009-07-31 14:58:03 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.6403898393703924" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.4671538099588498">
<NAME>Meconium-stained liquor</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.220339253228541" CI_START="0.2737113312101215" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9148897412340661" LOG_CI_START="-0.5627072231227036" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="6362" O_E="0.0" SE="0.8679477710861024" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.7533333333333332" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="66.61522199816511" CI_START="0.11922423317225214" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8181818181818183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.09" LOG_CI_END="1.8235734795372827" LOG_CI_START="-0.9236354621851873" LOG_EFFECT_SIZE="0.44996900867604767" METHOD="MH" MODIFIED="2009-07-31 14:58:09 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.5208405806790171" Q="0.0" RANDOM="NO" SCALE="310.38" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="0.6420502188750803">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="66.61522199816511" CI_START="0.11922423317225214" EFFECT_SIZE="2.8181818181818183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8235734795372827" LOG_CI_START="-0.9236354621851873" LOG_EFFECT_SIZE="0.44996900867604767" ORDER="6363" O_E="0.0" SE="1.6137241312713606" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="2.6041055718475072" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-008.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 14:58:16 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="158" WEIGHT="0.0" Z="0.0">
<NAME>Maternal side-effects</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-31 12:40:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="133" TOTAL_2="128" WEIGHT="0.0" Z="0.0">
<NAME>GI side-effects (nausea, vomitting or diarrhea)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6364" O_E="0.0" SE="0.0" STUDY_ID="STD-Clarke-1980" TOTAL_1="133" TOTAL_2="128" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-31 12:41:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Non-GI side-effects (fevers)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6365" O_E="0.0" SE="0.0" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="35.022577830052334" CI_START="2.26486152582508" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.90625" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-008.11" LOG_CI_END="1.5443481090850726" LOG_CI_START="0.35504165429213563" LOG_EFFECT_SIZE="0.9496948816886043" METHOD="MH" MODIFIED="2009-07-31 14:58:22 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.0017470309566556671" Q="0.0" RANDOM="NO" SCALE="136.21" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="3.1301734837313457">
<NAME>Maternal satisfaction - embarassment</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.022577830052334" CI_START="2.2648615258250806" EFFECT_SIZE="8.90625" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" LOG_CI_END="1.5443481090850726" LOG_CI_START="0.3550416542921357" LOG_EFFECT_SIZE="0.9496948816886043" ORDER="6366" O_E="0.0" SE="0.6986044987072693" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="0.48804824561403504" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2009-07-31 14:59:54 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Extra-amniotic PGE2 vs vaginal PGE2: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3609645331288802" CI_START="0.805767070763878" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0471964501815247" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="0.13384680759340178" LOG_CI_START="-0.09379048487238148" LOG_EFFECT_SIZE="0.02002816136051016" METHOD="MH" MODIFIED="2009-07-31 14:58:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.7301799622273435" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="59" WEIGHT="100.0" Z="0.3448861521585448">
<NAME>Vaginal delivery not achieved in 24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3609645331288802" CI_START="0.805767070763878" EFFECT_SIZE="1.0471964501815247" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="37" LOG_CI_END="0.13384680759340178" LOG_CI_START="-0.09379048487238148" LOG_EFFECT_SIZE="0.02002816136051016" ORDER="6367" O_E="0.0" SE="0.133715272417172" STUDY_ID="STD-Clarke-1980" TOTAL_1="67" TOTAL_2="59" VAR="0.017879774077598515" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 14:58:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6368" O_E="0.0" SE="0.0" STUDY_ID="STD-Clarke-1980" TOTAL_1="67" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1229315106516997" CI_END="1.8895370865463788" CI_START="0.42037843978862205" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8912466843501328" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="0.27635542037284305" LOG_CI_START="-0.3763595660047406" LOG_EFFECT_SIZE="-0.05000207281594874" METHOD="MH" MODIFIED="2009-07-31 14:58:49 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5703725733656868" P_Q="0.0" P_Z="0.7639550954587279" Q="0.0" RANDOM="NO" SCALE="42.46" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="70" WEIGHT="100.0" Z="0.3002911344674299">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.1178990744020965" CI_START="0.37944106248569703" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6146756982879912" LOG_CI_START="-0.42085567227187837" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="6369" O_E="0.0" SE="0.608276253029822" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.37000000000000005" WEIGHT="32.891246684350136"/>
<DICH_DATA CI_END="2.917064814565508" CI_START="0.30129815615047" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4649460788630513" LOG_CI_START="-0.5210035260635382" LOG_EFFECT_SIZE="-0.02802872360024354" ORDER="6370" O_E="0.0" SE="0.5791516784631352" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="0.3354166666666667" WEIGHT="42.44031830238727"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="6371" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="24.668435013262602"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.299548383635253" CI_START="3.5004516163647454" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.3999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.04" MODIFIED="2009-07-31 14:58:56 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="9.080931447230152E-22" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="9.586856792655864">
<NAME>Maternal satisfaction</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.299548383635253" CI_START="3.5004516163647454" DF="0.0" EFFECT_SIZE="4.3999999999999995" ESTIMABLE="YES" I2="0.0" ID="CMP-009.04.01" NO="1" P_CHI2="1.0" P_Z="9.080931447230152E-22" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="9.586856792655864">
<NAME>assessment of discomfort</NAME>
<CONT_DATA CI_END="5.299548383635253" CI_START="3.5004516163647454" EFFECT_SIZE="4.3999999999999995" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="1.2" ORDER="6372" SD_1="1.7" SD_2="1.9" SE="0.4589616904855277" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7928110041592065" CI_START="0.821023451706804" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.213235294117647" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-009.05" LOG_CI_END="0.2535345092069215" LOG_CI_START="-0.08564443751954406" LOG_EFFECT_SIZE="0.08394503584368873" METHOD="MH" MODIFIED="2009-07-31 14:59:03 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.3319658072511775" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="0.9701619072910219">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7928110041592065" CI_START="0.821023451706804" EFFECT_SIZE="1.213235294117647" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" LOG_CI_END="0.2535345092069215" LOG_CI_START="-0.08564443751954406" LOG_EFFECT_SIZE="0.08394503584368873" ORDER="6373" O_E="0.0" SE="0.1992353922699901" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="0.03969474153297683" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 14:59:14 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation without FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6374" O_E="0.0" SE="0.0" STUDY_ID="STD-Clarke-1980" TOTAL_1="67" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.363369663078036" CI_END="1.5526440007665367" CI_START="0.603846177618648" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9682758620689655" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-009.07" LOG_CI_END="0.19107188958170207" LOG_CI_START="-0.21907367846407888" LOG_EFFECT_SIZE="-0.01400089444118841" METHOD="MH" MODIFIED="2009-07-31 14:59:21 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8338641494348781" P_Q="0.0" P_Z="0.8935510471406517" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="70" WEIGHT="100.0" Z="0.133812241282165">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.243672097930701" CI_START="0.445697925700588" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.35095938713636066" LOG_CI_START="-0.35095938713636066" LOG_EFFECT_SIZE="0.0" ORDER="6375" O_E="0.0" SE="0.412310562561766" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.16999999999999998" WEIGHT="34.206896551724135"/>
<DICH_DATA CI_END="1.6445857530644812" CI_START="0.44906468954194073" EFFECT_SIZE="0.859375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.21605652367561667" LOG_CI_START="-0.34769109265490333" LOG_EFFECT_SIZE="-0.06581728448964332" ORDER="6376" O_E="0.0" SE="0.33114814042825447" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="0.10965909090909093" WEIGHT="52.9655172413793"/>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="6377" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="12.827586206896552"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.220339253228541" CI_START="0.2737113312101215" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.08" LOG_CI_END="0.9148897412340661" LOG_CI_START="-0.5627072231227036" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2009-07-31 14:59:34 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.6403898393703924" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.4671538099588498">
<NAME>Meconium-stained liquor</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.220339253228541" CI_START="0.2737113312101215" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9148897412340661" LOG_CI_START="-0.5627072231227036" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="6378" O_E="0.0" SE="0.8679477710861024" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.7533333333333332" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="66.61522199816511" CI_START="0.11922423317225214" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8181818181818183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.09" LOG_CI_END="1.8235734795372827" LOG_CI_START="-0.9236354621851873" LOG_EFFECT_SIZE="0.44996900867604767" METHOD="MH" MODIFIED="2009-07-31 14:59:41 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.5208405806790171" Q="0.0" RANDOM="NO" SCALE="266.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="0.6420502188750803">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="66.61522199816511" CI_START="0.11922423317225214" EFFECT_SIZE="2.8181818181818183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8235734795372827" LOG_CI_START="-0.9236354621851873" LOG_EFFECT_SIZE="0.44996900867604767" ORDER="6379" O_E="0.0" SE="1.6137241312713606" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="2.6041055718475072" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 14:59:47 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="89" WEIGHT="0.0" Z="0.0">
<NAME>Maternal side-effects</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-31 12:42:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="67" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>GI side-effects (nausea, vomitting or diarrhea)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6380" O_E="0.0" SE="0.0" STUDY_ID="STD-Clarke-1980" TOTAL_1="67" TOTAL_2="59" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-009.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-31 12:42:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Non-GI side-effects (fevers)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6381" O_E="0.0" SE="0.0" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="35.022577830052334" CI_START="2.26486152582508" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.90625" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-009.11" LOG_CI_END="1.5443481090850726" LOG_CI_START="0.35504165429213563" LOG_EFFECT_SIZE="0.9496948816886043" METHOD="MH" MODIFIED="2009-07-31 14:59:54 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.0017470309566556671" Q="0.0" RANDOM="NO" SCALE="94.46" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="30" WEIGHT="100.0" Z="3.1301734837313457">
<NAME>Maternal satisfaction - embarassment</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.022577830052334" CI_START="2.2648615258250806" EFFECT_SIZE="8.90625" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="2" LOG_CI_END="1.5443481090850726" LOG_CI_START="0.3550416542921357" LOG_EFFECT_SIZE="0.9496948816886043" ORDER="6382" O_E="0.0" SE="0.6986044987072693" STUDY_ID="STD-Stewart-1985" TOTAL_1="32" TOTAL_2="30" VAR="0.48804824561403504" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2009-07-31 15:00:04 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Extra-amniotic PGE2 vs vaginal PGE2: all women, favourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.318520624588564" CI_START="1.0606738576295531" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5681818181818181" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.3652109635508507" LOG_CI_START="0.025581864951285053" LOG_EFFECT_SIZE="0.19539641425106788" METHOD="MH" MODIFIED="2009-07-31 15:00:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.0241192398858033" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="69" WEIGHT="100.0" Z="2.2552245153286865">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.318520624588564" CI_START="1.0606738576295531" EFFECT_SIZE="1.5681818181818181" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" LOG_CI_END="0.3652109635508507" LOG_CI_START="0.025581864951285053" LOG_EFFECT_SIZE="0.19539641425106788" ORDER="6383" O_E="0.0" SE="0.1994998137085368" STUDY_ID="STD-Clarke-1980" TOTAL_1="66" TOTAL_2="69" VAR="0.03980017566974089" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2009-07-31 15:00:30 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Extra-amniotic PGE2 vs vaginal PGE2: all primiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3168515533325424" CI_START="0.7901698993257413" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.020066889632107" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="0.11953682036635838" LOG_CI_START="-0.10227951832164602" LOG_EFFECT_SIZE="0.008628651022356186" METHOD="MH" MODIFIED="2009-07-31 15:00:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8788043277010159" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="61" WEIGHT="100.0" Z="0.1524851175437548">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3168515533325424" CI_START="0.7901698993257413" EFFECT_SIZE="1.020066889632107" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" LOG_CI_END="0.11953682036635838" LOG_CI_START="-0.10227951832164602" LOG_EFFECT_SIZE="0.008628651022356186" ORDER="6384" O_E="0.0" SE="0.13029601535391874" STUDY_ID="STD-Clarke-1980" TOTAL_1="69" TOTAL_2="61" VAR="0.01697705161710863" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1280720372424102" CI_END="2.3370579861911978" CI_START="0.31436698699478227" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="11.353178965014003" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="0.3686694880749161" LOG_CI_START="-0.5025630673361425" LOG_EFFECT_SIZE="-0.06694678963061322" METHOD="MH" MODIFIED="2009-07-31 15:00:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.28818698969610024" P_Q="0.0" P_Z="0.7632520590244538" Q="0.0" RANDOM="NO" SCALE="43.51" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.3012130245630534">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.1178990744020965" CI_START="0.37944106248569703" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6146756982879912" LOG_CI_START="-0.42085567227187837" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="6385" O_E="0.0" SE="0.608276253029822" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.37000000000000005" WEIGHT="57.142857142857146"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="6386" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="42.85714285714286"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.134021237117241" CI_END="2.1713044311455643" CI_START="0.5480957103745329" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="0.336720718662921" LOG_CI_START="-0.2611435968841215" LOG_EFFECT_SIZE="0.037788560889399754" METHOD="MH" MODIFIED="2009-07-31 15:00:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7142986770254576" P_Q="0.0" P_Z="0.8043180687053207" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.24776263257342607">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.243672097930701" CI_START="0.445697925700588" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.35095938713636066" LOG_CI_START="-0.35095938713636066" LOG_EFFECT_SIZE="0.0" ORDER="6387" O_E="0.0" SE="0.412310562561766" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.16999999999999998" WEIGHT="72.72727272727273"/>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="6388" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="27.272727272727273"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.220339253228541" CI_START="0.2737113312101215" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-011.04" LOG_CI_END="0.9148897412340661" LOG_CI_START="-0.5627072231227036" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2009-07-31 15:00:30 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.6403898393703924" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.4671538099588498">
<NAME>Meconium-stained liquor</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.220339253228541" CI_START="0.2737113312101215" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9148897412340661" LOG_CI_START="-0.5627072231227036" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="6389" O_E="0.0" SE="0.8679477710861024" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.7533333333333332" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2009-07-31 15:00:57 +0100" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Extra-amniotic PGE2 vs vaginal PGE2: all primiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4510367086494973" CI_START="0.7322861254257917" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0308123249299719" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="0.16167839945514204" LOG_CI_START="-0.13531919433249323" LOG_EFFECT_SIZE="0.013179602561324416" METHOD="MH" MODIFIED="2009-07-31 15:00:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8619038013739655" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="32" WEIGHT="99.99999999999999" Z="0.17395121638068395">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4510367086494973" CI_START="0.7322861254257917" EFFECT_SIZE="1.0308123249299719" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.16167839945514204" LOG_CI_START="-0.13531919433249323" LOG_EFFECT_SIZE="0.013179602561324416" ORDER="6390" O_E="0.0" SE="0.17445785675265668" STUDY_ID="STD-Clarke-1980" TOTAL_1="34" TOTAL_2="32" VAR="0.03043554378273048" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1280720372424102" CI_END="2.3370579861911978" CI_START="0.31436698699478227" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="11.353178965014003" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="0.3686694880749161" LOG_CI_START="-0.5025630673361425" LOG_EFFECT_SIZE="-0.06694678963061322" METHOD="MH" MODIFIED="2009-07-31 15:00:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.28818698969610024" P_Q="0.0" P_Z="0.7632520590244538" Q="0.0" RANDOM="NO" SCALE="35.21" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.3012130245630534">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.1178990744020965" CI_START="0.37944106248569703" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6146756982879912" LOG_CI_START="-0.42085567227187837" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="6391" O_E="0.0" SE="0.608276253029822" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.37000000000000005" WEIGHT="57.142857142857146"/>
<DICH_DATA CI_END="2.8531415452949767" CI_START="0.03894342756823292" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.45532331768430767" LOG_CI_START="-1.4095658271236327" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="6392" O_E="0.0" SE="1.0954451150103321" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="1.2" WEIGHT="42.85714285714286"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.134021237117241" CI_END="2.1713044311455643" CI_START="0.5480957103745329" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="0.336720718662921" LOG_CI_START="-0.2611435968841215" LOG_EFFECT_SIZE="0.037788560889399754" METHOD="MH" MODIFIED="2009-07-31 15:00:51 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7142986770254576" P_Q="0.0" P_Z="0.8043180687053207" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.24776263257342607">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.243672097930701" CI_START="0.445697925700588" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.35095938713636066" LOG_CI_START="-0.35095938713636066" LOG_EFFECT_SIZE="0.0" ORDER="6393" O_E="0.0" SE="0.412310562561766" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.16999999999999998" WEIGHT="72.72727272727273"/>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.44606461734604286" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="6394" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="27.272727272727273"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.220339253228541" CI_START="0.2737113312101215" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-012.04" LOG_CI_END="0.9148897412340661" LOG_CI_START="-0.5627072231227036" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2009-07-31 15:00:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.6403898393703924" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.4671538099588498">
<NAME>Meconium-stained liquor</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.220339253228541" CI_START="0.2737113312101215" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9148897412340661" LOG_CI_START="-0.5627072231227036" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="6395" O_E="0.0" SE="0.8679477710861024" STUDY_ID="STD-Greer-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.7533333333333332" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2009-07-31 15:03:40 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Extra-amniotic PGE2 vs vaginal PGE2: all primiparae, favourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4835889034482834" CI_START="0.6912683646380714" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0126984126984127" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.17131357634894165" LOG_CI_START="-0.16035331781378045" LOG_EFFECT_SIZE="0.0054801292675805986" METHOD="MH" MODIFIED="2009-07-31 15:03:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.9483579746217257" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="29" WEIGHT="100.0" Z="0.06476893644870187">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4835889034482834" CI_START="0.6912683646380714" EFFECT_SIZE="1.0126984126984127" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.17131357634894165" LOG_CI_START="-0.16035331781378045" LOG_EFFECT_SIZE="0.0054801292675805986" ORDER="6396" O_E="0.0" SE="0.1948227754087873" STUDY_ID="STD-Clarke-1980" TOTAL_1="35" TOTAL_2="29" VAR="0.037955913817982787" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2009-07-31 15:03:49 +0100" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Extra-amniotic PGE2 vs vaginal PGE2: all multiparae (without prior CS)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5062394042682143" CI_START="1.1067711516934577" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6654829545454546" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.39902255388343016" LOG_CI_START="0.04405783060658722" LOG_EFFECT_SIZE="0.2215401922450087" METHOD="MH" MODIFIED="2009-07-31 15:03:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.014425034605889708" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="67" WEIGHT="100.00000000000001" Z="2.446501127886157">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5062394042682143" CI_START="1.1067711516934577" EFFECT_SIZE="1.6654829545454546" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="22" LOG_CI_END="0.39902255388343016" LOG_CI_START="0.04405783060658722" LOG_EFFECT_SIZE="0.2215401922450087" ORDER="6397" O_E="0.0" SE="0.20850803555653596" STUDY_ID="STD-Clarke-1980" TOTAL_1="64" TOTAL_2="67" VAR="0.04347560089164566" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2009-07-31 15:03:58 +0100" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Extra-amniotic PGE2 vs vaginal PGE2: all multiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6106598520864277" CI_START="0.7159693637426389" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0738636363636365" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="0.20700383343013376" LOG_CI_START="-0.14510556071194503" LOG_EFFECT_SIZE="0.030949136359094364" METHOD="MH" MODIFIED="2009-07-31 15:03:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.7304346370125191" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="27" WEIGHT="100.0" Z="0.3445474254627107">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6106598520864277" CI_START="0.715969363742639" EFFECT_SIZE="1.0738636363636365" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.20700383343013376" LOG_CI_START="-0.14510556071194497" LOG_EFFECT_SIZE="0.030949136359094364" ORDER="6398" O_E="0.0" SE="0.2068308010886683" STUDY_ID="STD-Clarke-1980" TOTAL_1="33" TOTAL_2="27" VAR="0.04277898027898028" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2009-07-31 15:04:05 +0100" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Extra-amniotic PGE2 vs vaginal PGE2: all multiparae, favourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.928642441879566" CI_START="1.3082839568318343" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.010752688172043" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="0.8406481497984961" LOG_CI_START="0.116702015778072" LOG_EFFECT_SIZE="0.4786750827882841" METHOD="MH" MODIFIED="2009-07-31 15:04:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.00954567624461857" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="40" WEIGHT="100.0" Z="2.5918666554694174">
<NAME>Vaginal delivery not achieved within 24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.928642441879566" CI_START="1.3082839568318343" EFFECT_SIZE="3.010752688172043" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.8406481497984961" LOG_CI_START="0.116702015778072" LOG_EFFECT_SIZE="0.4786750827882841" ORDER="6399" O_E="0.0" SE="0.42524954271475596" STUDY_ID="STD-Clarke-1980" TOTAL_1="31" TOTAL_2="40" VAR="0.18083717357910906" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2009-07-31 15:04:58 +0100" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Extra-amniotic PGE2 vs cervical PGE2: all women</NAME>
<DICH_OUTCOME CHI2="1.8343782459290572E-32" CI_END="9.110619666466738" CI_START="0.014742073656658989" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3664825046040515" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="99.99999999999999" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="0.9595479168824146" LOG_CI_START="-1.8314414232406955" LOG_EFFECT_SIZE="-0.43594675317914033" METHOD="MH" MODIFIED="2009-07-31 15:04:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.5403494614148833" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="100" WEIGHT="100.0" Z="0.6122846283394249">
<NAME>Hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.110619666466741" CI_START="0.014742073656659001" EFFECT_SIZE="0.3664825046040516" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9595479168824147" LOG_CI_START="-1.831441423240695" LOG_EFFECT_SIZE="-0.4359467531791403" MODIFIED="2008-08-05 20:56:49 +0100" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="1.6394409540083639" STUDY_ID="STD-Allouche-1993" TOTAL_1="90" TOTAL_2="100" VAR="2.687766641679854" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.726841682060513" CI_START="0.5950479745216509" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4891774891774892" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="0.5713409441174321" LOG_CI_START="-0.22544801875866055" LOG_EFFECT_SIZE="0.1729464626793858" METHOD="MH" MODIFIED="2009-07-31 15:04:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.3948598122898944" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="95" WEIGHT="100.0" Z="0.850837182487201">
<NAME>Meconium-stained liquor</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.726841682060513" CI_START="0.595047974521651" EFFECT_SIZE="1.4891774891774892" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.5713409441174321" LOG_CI_START="-0.22544801875866044" LOG_EFFECT_SIZE="0.1729464626793858" MODIFIED="2008-08-05 20:58:20 +0100" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.4680377809623937" STUDY_ID="STD-Allouche-1993" TOTAL_1="89" TOTAL_2="95" VAR="0.2190593644082016" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.17237903971899873" CI_END="1.299193214829199" CI_START="0.4279892952906949" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.745681425584144" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="0.11367374375521849" LOG_CI_START="-0.3685670932632779" LOG_EFFECT_SIZE="-0.1274466747540297" METHOD="MH" MODIFIED="2009-07-31 15:04:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6780063656579512" P_Q="0.0" P_Z="0.3002212372359232" Q="0.0" RANDOM="NO" SCALE="44.23" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="191" TOTAL_2="193" WEIGHT="100.0" Z="1.0359591029728894">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3681111719042907" CI_START="0.43669466378445276" EFFECT_SIZE="0.7729468599033816" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="23" LOG_CI_END="0.13612138933063705" LOG_CI_START="-0.359822114932623" LOG_EFFECT_SIZE="-0.11185036280099296" MODIFIED="2008-10-30 18:47:22 +0000" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.2913196693641782" STUDY_ID="STD-Allouche-1993" TOTAL_1="90" TOTAL_2="100" VAR="0.08486714975845411" WEIGHT="91.2764796799709"/>
<DICH_DATA CI_END="4.993835594081406" CI_START="0.04244523258519515" EFFECT_SIZE="0.4603960396039604" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6984342405066102" LOG_CI_START="-1.3721710822919875" LOG_EFFECT_SIZE="-0.33686842089268865" ORDER="6400" O_E="0.0" SE="1.2162838162735485" STUDY_ID="STD-Parewicjk-1986" TOTAL_1="101" TOTAL_2="93" VAR="1.479346321728947" WEIGHT="8.723520320029094"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8341382148140085E-32" CI_END="9.224815426129076" CI_START="0.014920580660098662" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.37099811676082856" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="100.0" I2_Q="0.0" ID="CMP-017.04" LOG_CI_END="0.9649576853768355" LOG_CI_START="-1.8262142752165882" LOG_EFFECT_SIZE="-0.4306282949198762" METHOD="MH" MODIFIED="2009-07-31 15:04:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.5453283017944289" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="99" WEIGHT="100.0" Z="0.6047753135119673">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.224815426129076" CI_START="0.014920580660098676" EFFECT_SIZE="0.3709981167608286" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9649576853768355" LOG_CI_START="-1.8262142752165877" LOG_EFFECT_SIZE="-0.43062829491987614" MODIFIED="2008-08-05 20:59:27 +0100" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="1.639548226176612" STUDY_ID="STD-Allouche-1993" TOTAL_1="88" TOTAL_2="99" VAR="2.6881183859588744" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.105868955720164" CI_START="0.19334799146634285" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.638095238095238" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-017.05" LOG_CI_END="0.32343134235832877" LOG_CI_START="-0.713660335096552" LOG_EFFECT_SIZE="-0.19511449636911166" METHOD="MH" MODIFIED="2009-07-31 15:04:27 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.46083027185706316" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="74" WEIGHT="100.0" Z="0.7374803868518505">
<NAME>"Other" maternal infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.105868955720164" CI_START="0.19334799146634285" EFFECT_SIZE="0.638095238095238" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.32343134235832877" LOG_CI_START="-0.713660335096552" LOG_EFFECT_SIZE="-0.19511449636911166" MODIFIED="2008-08-05 21:01:15 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.6091927850235954" STUDY_ID="STD-Allouche-1993" TOTAL_1="80" TOTAL_2="74" VAR="0.3711158493248045" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.200270856513239" CI_START="0.41767736580510173" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9586466165413534" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-017.06" LOG_CI_END="0.3424761463897005" LOG_CI_START="-0.3791590587839241" LOG_EFFECT_SIZE="-0.0183414561971118" METHOD="MH" MODIFIED="2009-07-31 15:04:30 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.9206373368266128" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="99" WEIGHT="100.0" Z="0.0996309307324022">
<NAME>All maternal side-effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.200270856513239" CI_START="0.4176773658051018" EFFECT_SIZE="0.9586466165413534" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.3424761463897005" LOG_CI_START="-0.37915905878392403" LOG_EFFECT_SIZE="-0.0183414561971118" MODIFIED="2008-10-31 17:47:55 +0000" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.42389209167086356" STUDY_ID="STD-Allouche-1993" TOTAL_1="88" TOTAL_2="99" VAR="0.1796845053810998" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2486916316132004E-32" CI_END="4.717820905883521" CI_START="0.18021618695258917" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9220779220779219" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="100.0" I2_Q="0.0" ID="CMP-017.07" LOG_CI_END="0.6737414505252416" LOG_CI_START="-0.744206203432055" LOG_EFFECT_SIZE="-0.035232376453406655" METHOD="MH" MODIFIED="2009-07-31 15:04:33 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.9224085899524369" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="74" WEIGHT="100.0" Z="0.0974001949165237">
<NAME>"Other" maternal fever other than infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.717820905883522" CI_START="0.18021618695258923" EFFECT_SIZE="0.922077922077922" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6737414505252417" LOG_CI_START="-0.7442062034320549" LOG_EFFECT_SIZE="-0.0352323764534066" MODIFIED="2008-08-05 21:05:24 +0100" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.8329094708886033" STUDY_ID="STD-Allouche-1993" TOTAL_1="80" TOTAL_2="74" VAR="0.6937381866959331" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.761118519513975" CI_START="0.269314772669944" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2456140350877194" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-017.08" LOG_CI_END="0.7605068097589796" LOG_CI_START="-0.5697398236658116" LOG_EFFECT_SIZE="0.09538349304658392" METHOD="MH" MODIFIED="2009-07-31 15:04:39 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.7786544040602761" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="74" WEIGHT="100.0" Z="0.2810730076566675">
<NAME>instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.761118519513975" CI_START="0.269314772669944" EFFECT_SIZE="1.2456140350877194" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7605068097589796" LOG_CI_START="-0.5697398236658116" LOG_EFFECT_SIZE="0.09538349304658392" MODIFIED="2008-10-31 15:03:08 +0000" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.7813934573007564" STUDY_ID="STD-Allouche-1993" TOTAL_1="80" TOTAL_2="74" VAR="0.6105757351124289" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7788955761623081" CI_START="0.2358127007123748" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-017.09" LOG_CI_END="-0.10852076278489187" LOG_CI_START="-0.6274328078042969" LOG_EFFECT_SIZE="-0.36797678529459443" METHOD="MH" MODIFIED="2009-07-31 15:04:48 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.005440181526502345" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="100" WEIGHT="100.0" Z="2.7797437089642534">
<NAME>Cervix unfavourable &gt; 12-24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Cervical PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7788955761623081" CI_START="0.2358127007123748" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="50" LOG_CI_END="-0.10852076278489187" LOG_CI_START="-0.6274328078042969" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2008-10-31 17:25:21 +0000" MODIFIED_BY="[Empty name]" ORDER="153" O_E="0.0" SE="0.30481150390044814" STUDY_ID="STD-Allouche-1993" TOTAL_1="90" TOTAL_2="100" VAR="0.09291005291005291" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.038684443093464846" CI_END="2.682689797348674" CI_START="0.05687537891962386" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.39061361823164176" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-017.10" LOG_CI_END="0.42857045758124956" LOG_CI_START="-1.2450756969343293" LOG_EFFECT_SIZE="-0.4082526196765399" METHOD="MH" MODIFIED="2009-07-31 15:04:58 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.8440752208231428" P_Q="0.0" P_Z="0.3389771245000771" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="148" WEIGHT="100.00000000000001" Z="0.9561882946419404">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.588283676113408" CI_START="0.012206660056137844" DF="0.0" EFFECT_SIZE="0.30434782608695654" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-017.10.01" LOG_CI_END="0.8801435579398553" LOG_CI_START="-1.9134031499465272" LOG_EFFECT_SIZE="-0.516629796003336" MODIFIED="2009-07-31 12:43:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.46848932073572425" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="74" WEIGHT="43.00183842658435" Z="0.7249392255717363">
<NAME>Chorioamnionitis</NAME>
<DICH_DATA CI_END="7.588283676113408" CI_START="0.012206660056137844" EFFECT_SIZE="0.30434782608695654" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8801435579398553" LOG_CI_START="-1.9134031499465272" LOG_EFFECT_SIZE="-0.516629796003336" MODIFIED="2008-10-31 17:50:36 +0000" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="1.6409431644916848" STUDY_ID="STD-Allouche-1993" TOTAL_1="80" TOTAL_2="74" VAR="2.6926944690919843" WEIGHT="43.00183842658435"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.132924062231066" CI_START="0.04045628310181972" DF="0.0" EFFECT_SIZE="0.45569620253164556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-017.10.02" LOG_CI_END="0.7103648392465474" LOG_CI_START="-1.3930140202928558" LOG_EFFECT_SIZE="-0.34132459052315417" MODIFIED="2009-07-31 12:43:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5247086104270813" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="74" WEIGHT="56.998161573415665" Z="0.6361040489013544">
<NAME>Endometritis</NAME>
<DICH_DATA CI_END="5.132924062231066" CI_START="0.04045628310181972" EFFECT_SIZE="0.45569620253164556" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7103648392465474" LOG_CI_START="-1.3930140202928558" LOG_EFFECT_SIZE="-0.34132459052315417" MODIFIED="2008-10-31 17:54:01 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="1.235535153986721" STUDY_ID="STD-Allouche-1993" TOTAL_1="80" TOTAL_2="74" VAR="1.5265471167369902" WEIGHT="56.998161573415665"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2009-07-31 15:05:04 +0100" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Extra-amniotic PGE2 vs cervical PGE2: all primiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.551446566965986" CI_START="0.01675138931869919" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="0.9800691504816983" LOG_CI_START="-1.7759491678257735" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" MODIFIED="2009-07-31 15:05:04 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.5713962986382161" Q="0.0" RANDOM="NO" SCALE="361.46" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="47" WEIGHT="100.0" Z="0.5659962996789752">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.55144656696598" CI_START="0.01675138931869919" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9800691504816981" LOG_CI_START="-1.7759491678257735" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="6402" O_E="0.0" SE="1.618898802684508" STUDY_ID="STD-Parewicjk-1986" TOTAL_1="39" TOTAL_2="47" VAR="2.620833333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2009-07-31 15:05:10 +0100" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Extra-amniotic PGE2 vs cervical PGE2: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.993835594081406" CI_START="0.04244523258519515" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4603960396039604" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="0.6984342405066102" LOG_CI_START="-1.3721710822919875" LOG_EFFECT_SIZE="-0.33686842089268865" METHOD="MH" MODIFIED="2009-07-31 15:05:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.5236454284396984" Q="0.0" RANDOM="NO" SCALE="71.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="93" WEIGHT="100.0" Z="0.6377361877792979">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.993835594081406" CI_START="0.04244523258519515" EFFECT_SIZE="0.4603960396039604" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6984342405066102" LOG_CI_START="-1.3721710822919875" LOG_EFFECT_SIZE="-0.33686842089268865" ORDER="6401" O_E="0.0" SE="1.2162838162735485" STUDY_ID="STD-Parewicjk-1986" TOTAL_1="101" TOTAL_2="93" VAR="1.479346321728947" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2009-07-31 15:05:14 +0100" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Extra-amniotic PGE2 vs cervical PGE2: all primiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.551446566965986" CI_START="0.01675138931869919" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.9800691504816983" LOG_CI_START="-1.7759491678257735" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" MODIFIED="2009-07-31 15:05:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.5713962986382161" Q="0.0" RANDOM="NO" SCALE="158.9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="47" WEIGHT="100.0" Z="0.5659962996789752">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.55144656696598" CI_START="0.01675138931869919" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9800691504816981" LOG_CI_START="-1.7759491678257735" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="6403" O_E="0.0" SE="1.618898802684508" STUDY_ID="STD-Parewicjk-1986" TOTAL_1="39" TOTAL_2="47" VAR="2.620833333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2009-07-31 15:05:19 +0100" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Extra-amniotic PGE2 vs cervical PGE2: all multiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.553038118511523" CI_START="0.04764705669453539" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="1.0626962062716676" LOG_CI_START="-1.3219639219050272" LOG_EFFECT_SIZE="-0.1296338578166798" METHOD="MH" MODIFIED="2009-07-31 15:05:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8312540961085699" Q="0.0" RANDOM="NO" SCALE="67.06" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="46" WEIGHT="100.0" Z="0.21309342115091745">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.553038118511523" CI_START="0.04764705669453539" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0626962062716676" LOG_CI_START="-1.3219639219050272" LOG_EFFECT_SIZE="-0.1296338578166798" ORDER="6404" O_E="0.0" SE="1.4007611635490016" STUDY_ID="STD-Parewicjk-1986" TOTAL_1="62" TOTAL_2="46" VAR="1.9621318373071528" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2009-07-31 15:05:23 +0100" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Extra-amniotic PGE2 vs cervical PGE2: all multiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="11.553038118511523" CI_START="0.04764705669453539" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="1.0626962062716676" LOG_CI_START="-1.3219639219050272" LOG_EFFECT_SIZE="-0.1296338578166798" METHOD="MH" MODIFIED="2009-07-31 15:05:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8312540961085699" Q="0.0" RANDOM="NO" SCALE="71.58" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="46" WEIGHT="100.0" Z="0.21309342115091745">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.553038118511523" CI_START="0.04764705669453539" EFFECT_SIZE="0.7419354838709677" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0626962062716676" LOG_CI_START="-1.3219639219050272" LOG_EFFECT_SIZE="-0.1296338578166798" ORDER="6405" O_E="0.0" SE="1.4007611635490016" STUDY_ID="STD-Parewicjk-1986" TOTAL_1="62" TOTAL_2="46" VAR="1.9621318373071528" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2009-07-31 15:05:41 +0100" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Extra-amniotic PGE2 vs oxytocin: all women</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5140742356037356" CI_START="0.02641878387425968" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="0.18014716930056518" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" MODIFIED="2009-07-31 15:05:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.11915467176373172" Q="0.0" RANDOM="NO" SCALE="85.65" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.5583315579030255">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxytocin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5140742356037356" CI_START="0.02641878387425968" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.18014716930056518" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="6406" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="1.0666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.321002428076126" CI_START="0.4291383926638037" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-023.02" LOG_CI_END="0.9694626211062671" LOG_CI_START="-0.36740262977830473" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2009-07-31 15:05:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.3774125641111259" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.8826737763993158">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxytocin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.321002428076126" CI_START="0.4291383926638037" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9694626211062671" LOG_CI_START="-0.36740262977830473" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="6407" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2009-07-31 15:05:56 +0100" MODIFIED_BY="[Empty name]" NO="24">
<NAME>Extra-amniotic PGE2 vs oxytocin: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5140742356037356" CI_START="0.02641878387425968" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="0.18014716930056518" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" MODIFIED="2009-07-31 15:05:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.11915467176373172" Q="0.0" RANDOM="NO" SCALE="56.03" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.5583315579030255">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxytocin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5140742356037356" CI_START="0.02641878387425968" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.18014716930056518" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="6408" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="1.0666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.321002428076126" CI_START="0.4291383926638037" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-024.02" LOG_CI_END="0.9694626211062671" LOG_CI_START="-0.36740262977830473" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2009-07-31 15:05:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.3774125641111259" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.8826737763993158">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxytocin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.321002428076126" CI_START="0.4291383926638037" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9694626211062671" LOG_CI_START="-0.36740262977830473" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="6409" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2009-07-31 15:06:05 +0100" MODIFIED_BY="[Empty name]" NO="25">
<NAME>Extra-amniotic PGE2 vs oxytocin: all primiparae</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5140742356037356" CI_START="0.02641878387425968" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="0.18014716930056518" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" MODIFIED="2009-07-31 15:06:05 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.11915467176373172" Q="0.0" RANDOM="NO" SCALE="57.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.5583315579030255">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxytocin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5140742356037356" CI_START="0.02641878387425968" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.18014716930056518" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="6410" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="1.0666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.321002428076126" CI_START="0.4291383926638037" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-025.02" LOG_CI_END="0.9694626211062671" LOG_CI_START="-0.36740262977830473" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2008-11-18 19:33:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.3774125641111259" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.8826737763993158">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>EA PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxytocin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.321002428076126" CI_START="0.4291383926638037" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9694626211062671" LOG_CI_START="-0.36740262977830473" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="6411" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2009-07-31 15:06:17 +0100" MODIFIED_BY="[Empty name]" NO="26">
<NAME>Extra-amniotic PGE2 vs oxytocin: all primiparae, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5140742356037356" CI_START="0.02641878387425968" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="0.18014716930056518" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" MODIFIED="2008-11-18 19:33:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.11915467176373172" Q="0.0" RANDOM="NO" SCALE="69.28325660434268" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.5583315579030255">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxytocin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5140742356037356" CI_START="0.02641878387425968" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.18014716930056518" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="6412" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="1.0666666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.321002428076126" CI_START="0.4291383926638037" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-026.02" LOG_CI_END="0.9694626211062671" LOG_CI_START="-0.36740262977830473" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2009-07-31 15:06:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.3774125641111259" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.8826737763993158">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Oxytocin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.321002428076126" CI_START="0.4291383926638037" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9694626211062671" LOG_CI_START="-0.36740262977830473" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="6413" O_E="0.0" SE="0.7852812659593165" STUDY_ID="STD-Wilson-1978" TOTAL_1="15" TOTAL_2="15" VAR="0.6166666666666667" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2009-07-31 15:11:40 +0100" MODIFIED_BY="[Empty name]" NO="27">
<NAME>Extra-amniotic PGF2 alpha vs Foley catheter: all women</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 15:06:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Foley catheter</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6414" O_E="0.0" SE="0.0" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9933020956744298" CI_START="0.5284317424883866" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-027.02" LOG_CI_END="0.2995731233577835" LOG_CI_START="-0.2770111025384054" LOG_EFFECT_SIZE="0.011281010409689084" METHOD="MH" MODIFIED="2009-07-31 15:06:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.9388667051478573" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="0.07669434271409607">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2A</GROUP_LABEL_1>
<GROUP_LABEL_2>Foley catheter</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9933020956744298" CI_START="0.5284317424883866" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.2995731233577835" LOG_CI_START="-0.2770111025384054" LOG_EFFECT_SIZE="0.011281010409689084" ORDER="6415" O_E="0.0" SE="0.33868842842937047" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.11470985155195682" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 15:06:50 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Extra-amniotic PGf2A</GROUP_LABEL_1>
<GROUP_LABEL_2>Foley catheter</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6416" O_E="0.0" SE="0.0" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0087409076653926" CI_START="0.677599975888902" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8267543859649122" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-027.04" LOG_CI_END="0.0037796332136027294" LOG_CI_START="-0.16902661813088699" LOG_EFFECT_SIZE="-0.08262349245864214" METHOD="MH" MODIFIED="2009-07-31 15:06:56 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.06089914663657733" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="1.8742269823680089">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0087409076653926" CI_START="0.677599975888902" EFFECT_SIZE="0.8267543859649122" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.0037796332136027294" LOG_CI_START="-0.16902661813088699" LOG_EFFECT_SIZE="-0.08262349245864214" ORDER="6417" O_E="0.0" SE="0.10150724744449326" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.010303721283757582" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.91950060052885" CI_START="0.1522254510162897" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-027.05" LOG_CI_END="0.8400747513554508" LOG_CI_START="-0.8175127305360728" LOG_EFFECT_SIZE="0.011281010409689084" METHOD="MH" MODIFIED="2009-07-31 15:07:39 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.9787167386755284" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="0.0266777764115125">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.919500600528848" CI_START="0.15222545101628973" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8400747513554507" LOG_CI_START="-0.8175127305360728" LOG_EFFECT_SIZE="0.011281010409689084" ORDER="6418" O_E="0.0" SE="0.9736750920534478" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.9480431848852902" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.232546465138056" CI_START="0.36122485083442424" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8980263157894737" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-027.06" LOG_CI_END="0.3488005064600522" LOG_CI_START="-0.4422223795960476" LOG_EFFECT_SIZE="-0.046710936567997706" METHOD="MH" MODIFIED="2009-07-31 15:11:33 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.8169443479201681" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="0.2314768762604869">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.232546465138056" CI_START="0.36122485083442424" EFFECT_SIZE="0.8980263157894737" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3488005064600522" LOG_CI_START="-0.4422223795960476" LOG_EFFECT_SIZE="-0.046710936567997706" ORDER="6419" O_E="0.0" SE="0.4646507588957894" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.215900327742433" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-027.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 15:11:40 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6420" O_E="0.0" SE="0.0" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2009-07-31 15:12:29 +0100" MODIFIED_BY="[Empty name]" NO="28">
<NAME>Extra-amniotic PGF2 alpha vs Foley catheter: all women, unfavourable cervix</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-028.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 15:11:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Uterine hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Extra-amniotic PGF2 alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Foley catheter</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6421" O_E="0.0" SE="0.0" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9933020956744298" CI_START="0.5284317424883866" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-028.02" LOG_CI_END="0.2995731233577835" LOG_CI_START="-0.2770111025384054" LOG_EFFECT_SIZE="0.011281010409689084" METHOD="MH" MODIFIED="2009-07-31 15:11:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.9388667051478573" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="0.07669434271409607">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9933020956744298" CI_START="0.5284317424883866" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.2995731233577835" LOG_CI_START="-0.2770111025384054" LOG_EFFECT_SIZE="0.011281010409689084" ORDER="6422" O_E="0.0" SE="0.33868842842937047" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.11470985155195682" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-028.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 15:12:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Serious neonatal morbidity or perinatal death</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6423" O_E="0.0" SE="0.0" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0087409076653926" CI_START="0.677599975888902" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8267543859649122" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-028.04" LOG_CI_END="0.0037796332136027294" LOG_CI_START="-0.16902661813088699" LOG_EFFECT_SIZE="-0.08262349245864214" METHOD="MH" MODIFIED="2009-07-31 15:12:10 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.06089914663657733" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="1.8742269823680089">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0087409076653926" CI_START="0.677599975888902" EFFECT_SIZE="0.8267543859649122" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.0037796332136027294" LOG_CI_START="-0.16902661813088699" LOG_EFFECT_SIZE="-0.08262349245864214" ORDER="6424" O_E="0.0" SE="0.10150724744449326" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.010303721283757582" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.91950060052885" CI_START="0.1522254510162897" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-028.05" LOG_CI_END="0.8400747513554508" LOG_CI_START="-0.8175127305360728" LOG_EFFECT_SIZE="0.011281010409689084" METHOD="MH" MODIFIED="2009-07-31 15:12:15 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.9787167386755284" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="0.0266777764115125">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.919500600528848" CI_START="0.15222545101628973" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8400747513554507" LOG_CI_START="-0.8175127305360728" LOG_EFFECT_SIZE="0.011281010409689084" ORDER="6425" O_E="0.0" SE="0.9736750920534478" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.9480431848852902" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.232546465138056" CI_START="0.36122485083442424" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8980263157894737" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-028.06" LOG_CI_END="0.3488005064600522" LOG_CI_START="-0.4422223795960476" LOG_EFFECT_SIZE="-0.046710936567997706" METHOD="MH" MODIFIED="2009-07-31 15:12:22 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.8169443479201681" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="100.0" Z="0.2314768762604869">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.232546465138056" CI_START="0.36122485083442424" EFFECT_SIZE="0.8980263157894737" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3488005064600522" LOG_CI_START="-0.4422223795960476" LOG_EFFECT_SIZE="-0.046710936567997706" ORDER="6426" O_E="0.0" SE="0.4646507588957894" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.215900327742433" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-028.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 15:12:29 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal PGE2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6427" O_E="0.0" SE="0.0" STUDY_ID="STD-Mahomed-1988" TOTAL_1="38" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-029" MODIFIED="2009-07-31 15:13:19 +0100" MODIFIED_BY="[Empty name]" NO="29">
<NAME>Extra-amniotic PGE2 alpha vs Foley only: all women</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4721005662849986" CI_START="0.458059975722962" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8211640211640212" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-029.01" LOG_CI_END="0.16793747976423037" LOG_CI_START="-0.33907765426637937" LOG_EFFECT_SIZE="-0.08557008725107448" METHOD="MH" MODIFIED="2009-07-31 12:31:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.5082435862278472" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="97" WEIGHT="100.0" Z="0.6615750809360682">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4721005662849984" CI_START="0.45805997572296203" EFFECT_SIZE="0.8211640211640212" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.16793747976423032" LOG_CI_START="-0.3390776542663793" LOG_EFFECT_SIZE="-0.08557008725107448" MODIFIED="2008-10-30 18:43:23 +0000" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.29782319949497055" STUDY_ID="STD-Allouche-1993" TOTAL_1="90" TOTAL_2="97" VAR="0.08869865815742103" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-029.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 12:31:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="97" WEIGHT="0.0" Z="0.0">
<NAME>Hyperstimulation with FHR changes</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-05 21:12:50 +0100" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.0" STUDY_ID="STD-Allouche-1993" TOTAL_1="90" TOTAL_2="97" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6528176459230344" CI_START="0.6725745191387204" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5674157303370786" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-029.03" LOG_CI_END="0.5626279921281168" LOG_CI_START="-0.17225959019870968" LOG_EFFECT_SIZE="0.19518420096470357" METHOD="MH" MODIFIED="2009-07-31 12:31:48 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.29781870593254156" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="93" WEIGHT="100.0" Z="1.0411225157208164">
<NAME>Meconium-stained liquor</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6528176459230344" CI_START="0.6725745191387204" EFFECT_SIZE="1.5674157303370786" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5626279921281168" LOG_CI_START="-0.17225959019870968" LOG_EFFECT_SIZE="0.19518420096470357" MODIFIED="2008-08-05 21:13:54 +0100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.4316766036109793" STUDY_ID="STD-Allouche-1993" TOTAL_1="89" TOTAL_2="93" VAR="0.18634469010511054" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.25111733829583" CI_START="0.5068649142731932" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0681818181818181" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-029.04" LOG_CI_END="0.35239813295976324" LOG_CI_START="-0.2951077700607032" LOG_EFFECT_SIZE="0.02864518144953001" METHOD="MH" MODIFIED="2009-07-31 12:31:59 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.8623254639894877" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="94" WEIGHT="100.0" Z="0.17341470930163577">
<NAME>All maternal side-effects</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2511173382958303" CI_START="0.5068649142731932" EFFECT_SIZE="1.0681818181818181" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.35239813295976335" LOG_CI_START="-0.2951077700607032" LOG_EFFECT_SIZE="0.02864518144953001" MODIFIED="2008-10-31 17:47:29 +0000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.38034817264013493" STUDY_ID="STD-Allouche-1993" TOTAL_1="88" TOTAL_2="94" VAR="0.1446647324306899" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-029.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 12:32:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>Vomiting</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-05 21:15:25 +0100" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.0" STUDY_ID="STD-Allouche-1993" TOTAL_1="88" TOTAL_2="94" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.544469127994655" CI_START="0.18996998545301652" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-029.06" LOG_CI_END="0.18877923172094904" LOG_CI_START="-0.7213150105304876" LOG_EFFECT_SIZE="-0.2662678894047693" METHOD="MH" MODIFIED="2009-07-31 12:32:21 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.25143938607770744" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="78" WEIGHT="100.0" Z="1.146860290384434">
<NAME>"Other" maternal infection</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.544469127994655" CI_START="0.18996998545301652" EFFECT_SIZE="0.5416666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18877923172094904" LOG_CI_START="-0.7213150105304876" LOG_EFFECT_SIZE="-0.2662678894047693" MODIFIED="2008-08-05 21:16:28 +0100" MODIFIED_BY="[Empty name]" ORDER="138" O_E="0.0" SE="0.5345938629376494" STUDY_ID="STD-Allouche-1993" TOTAL_1="80" TOTAL_2="78" VAR="0.2857905982905983" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1616632311424" CI_START="0.16912824782631503" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.73125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-029.07" LOG_CI_END="0.4999156085925123" LOG_CI_START="-0.7717838504120387" LOG_EFFECT_SIZE="-0.13593412090976315" METHOD="MH" MODIFIED="2009-07-31 12:32:31 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.6752104502675003" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="78" WEIGHT="100.0" Z="0.41900777635275455">
<NAME>"Other" maternal fever other than infection</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1616632311424" CI_START="0.16912824782631503" EFFECT_SIZE="0.73125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4999156085925123" LOG_CI_START="-0.7717838504120387" LOG_EFFECT_SIZE="-0.13593412090976315" MODIFIED="2008-08-05 21:10:35 +0100" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.7470025572331199" STUDY_ID="STD-Allouche-1993" TOTAL_1="80" TOTAL_2="78" VAR="0.5580128205128205" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8615027941566799" CI_START="0.40938990331568714" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5938775510204082" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-029.08" LOG_CI_END="-0.06474330964385781" LOG_CI_START="-0.387862872441355" LOG_EFFECT_SIZE="-0.22630309104260635" METHOD="MH" MODIFIED="2009-07-31 15:13:19 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.006043754344476371" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="97" WEIGHT="100.0" Z="2.745398045190925">
<NAME>Cervix unfavourable &gt; 12-24 hours</NAME>
<GROUP_LABEL_1>Extra-amniotic PGE2</GROUP_LABEL_1>
<GROUP_LABEL_2>Foley catheter</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8615027941566797" CI_START="0.4093899033156872" EFFECT_SIZE="0.5938775510204082" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="49" LOG_CI_END="-0.06474330964385787" LOG_CI_START="-0.38786287244135487" LOG_EFFECT_SIZE="-0.22630309104260635" MODIFIED="2008-10-31 17:47:08 +0000" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.1898020306548815" STUDY_ID="STD-Allouche-1993" TOTAL_1="90" TOTAL_2="97" VAR="0.03602481084071658" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.315847163768868" CI_START="0.062068065176883985" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-029.09" LOG_CI_END="1.1851410238898707" LOG_CI_START="-1.2071317924927971" LOG_EFFECT_SIZE="-0.010995384301463193" METHOD="MH" MODIFIED="2009-07-31 12:43:46 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.9856254465957974" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="160" TOTAL_2="156" WEIGHT="100.0" Z="0.018016805674890665">
<NAME>Serious maternal complications</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-029.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-07-31 12:43:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Chorioamnionitis</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-31 17:55:58 +0000" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.0" STUDY_ID="STD-Allouche-1993" TOTAL_1="80" TOTAL_2="78" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.315847163768868" CI_START="0.062068065176883985" DF="0.0" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-029.09.02" LOG_CI_END="1.1851410238898707" LOG_CI_START="-1.2071317924927971" LOG_EFFECT_SIZE="-0.010995384301463193" MODIFIED="2009-07-31 12:43:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9856254465957974" STUDIES="1" TAU2="0.0" TOTAL_1="80" TOTAL_2="78" WEIGHT="100.0" Z="0.018016805674890665">
<NAME>Endometritis</NAME>
<DICH_DATA CI_END="15.315847163768876" CI_START="0.06206806517688396" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.185141023889871" LOG_CI_START="-1.2071317924927973" LOG_EFFECT_SIZE="-0.010995384301463193" MODIFIED="2008-10-31 17:59:13 +0000" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="1.4052328942846048" STUDY_ID="STD-Allouche-1993" TOTAL_1="80" TOTAL_2="78" VAR="1.9746794871794873" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="34.123126766261876" CI_START="0.445738753783794" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.9" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-029.10" LOG_CI_END="1.5330488195387637" LOG_CI_START="-0.35091960548576556" LOG_EFFECT_SIZE="0.5910646070264992" METHOD="MH" MODIFIED="2009-07-31 12:43:52 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.21876679959851653" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="78" WEIGHT="100.0" Z="1.2298139681329057">
<NAME>Instrumental vaginal delivery</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="34.123126766261876" CI_START="0.445738753783794" EFFECT_SIZE="3.9" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5330488195387637" LOG_CI_START="-0.35091960548576556" LOG_EFFECT_SIZE="0.5910646070264992" MODIFIED="2008-10-31 18:01:28 +0000" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.106652378653517" STUDY_ID="STD-Allouche-1993" TOTAL_1="80" TOTAL_2="78" VAR="1.2246794871794873" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-030" MODIFIED="2009-07-31 12:39:18 +0100" MODIFIED_BY="[Empty name]" NO="30">
<NAME>Extra-amniotic PGF2 alpha vs vaginal misoprostol</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.146884695201424" CI_START="1.422262642242815" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4285714285714284" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-030.01" LOG_CI_END="0.6177219599036994" LOG_CI_START="0.15297980282433474" LOG_EFFECT_SIZE="0.3853508813640171" METHOD="MH" MODIFIED="2009-07-31 12:36:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.001152865835070886" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="76" WEIGHT="100.0" Z="3.250291962453759">
<NAME>Vaginal delivery not achieved in 24 hours</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.146884695201424" CI_START="1.422262642242815" EFFECT_SIZE="2.4285714285714284" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="14" LOG_CI_END="0.6177219599036994" LOG_CI_START="0.15297980282433474" LOG_EFFECT_SIZE="0.3853508813640171" MODIFIED="2008-10-31 18:11:13 +0000" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.2729918435791985" STUDY_ID="STD-Majoko-2002a" TOTAL_1="76" TOTAL_2="76" VAR="0.07452454666076958" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.750366022198952" CI_START="0.9467996338713893" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-030.02" LOG_CI_END="0.7596954892743343" LOG_CI_START="-0.02374191868514543" LOG_EFFECT_SIZE="0.36797678529459443" METHOD="MH" MODIFIED="2009-07-31 12:36:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.06559645566319179" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="76" WEIGHT="100.0" Z="1.8411713277840716">
<NAME>Caesarean section</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.750366022198952" CI_START="0.9467996338713893" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7596954892743343" LOG_CI_START="-0.02374191868514543" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2008-08-05 21:56:17 +0100" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.46019501151311265" STUDY_ID="STD-Majoko-2002a" TOTAL_1="76" TOTAL_2="76" VAR="0.2117794486215539" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-030.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 12:36:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Serious maternal morbidity or death</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-05 21:56:54 +0100" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.0" STUDY_ID="STD-Majoko-2002a" TOTAL_1="76" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.489086676716094" CI_START="1.2034784317473526" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7307692307692308" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-030.04" LOG_CI_END="0.3960400201779313" LOG_CI_START="0.08043831143112017" LOG_EFFECT_SIZE="0.2382391658045257" METHOD="MH" MODIFIED="2009-07-31 12:37:00 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.003085917787555225" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="76" WEIGHT="100.0" Z="2.9590472531841443">
<NAME>Oxytocin augmentation</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.489086676716094" CI_START="1.2034784317473526" EFFECT_SIZE="1.7307692307692308" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="26" LOG_CI_END="0.3960400201779313" LOG_CI_START="0.08043831143112017" LOG_EFFECT_SIZE="0.2382391658045257" MODIFIED="2008-08-05 21:58:54 +0100" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="0.18538600597153088" STUDY_ID="STD-Majoko-2002a" TOTAL_1="76" TOTAL_2="76" VAR="0.03436797121007648" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-030.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-31 12:37:06 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Uterine rupture</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-05 21:59:20 +0100" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.0" STUDY_ID="STD-Majoko-2002a" TOTAL_1="76" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6713055907318948" CI_START="0.023933384906875875" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-030.06" LOG_CI_END="0.22305586595236604" LOG_CI_START="-1.6209958746244038" LOG_EFFECT_SIZE="-0.6989700043360187" METHOD="MH" MODIFIED="2009-07-31 12:37:13 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.13732916152641225" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.485810842101336">
<NAME>Meconium-stained liquor</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.671305590731894" CI_START="0.023933384906875896" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22305586595236584" LOG_CI_START="-1.6209958746244033" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2008-08-05 21:59:44 +0100" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="1.083205120618128" STUDY_ID="STD-Majoko-2002a" TOTAL_1="75" TOTAL_2="75" VAR="1.1733333333333331" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.055400470531458" CI_START="0.1740320139285748" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-030.07" LOG_CI_END="0.02341728346358943" LOG_CI_START="-0.7593708540527783" LOG_EFFECT_SIZE="-0.36797678529459443" METHOD="MH" MODIFIED="2009-07-31 12:37:39 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.06537304953861163" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="1.8426984563473996">
<NAME>Neonatal intensive care unit admission</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0554004705314577" CI_START="0.1740320139285748" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.023417283463589338" LOG_CI_START="-0.7593708540527783" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2008-08-05 22:00:18 +0100" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.459813626840888" STUDY_ID="STD-Majoko-2002a" TOTAL_1="75" TOTAL_2="75" VAR="0.2114285714285714" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.697660502905613" CI_START="0.06370376017591294" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.08" LOG_CI_END="1.1958349322572142" LOG_CI_START="-1.1958349322572142" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-07-31 12:38:01 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="76" WEIGHT="100.0" Z="0.0">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.697660502905613" CI_START="0.06370376017591294" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1958349322572142" LOG_CI_START="-1.1958349322572142" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-05 22:00:45 +0100" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="1.404878717372541" STUDY_ID="STD-Majoko-2002a" TOTAL_1="76" TOTAL_2="76" VAR="1.973684210526316" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="28.200466671586646" CI_START="0.3191436547774558" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-030.09" LOG_CI_END="1.4502562952419846" LOG_CI_START="-0.49601378580265976" LOG_EFFECT_SIZE="0.47712125471966244" METHOD="MH" MODIFIED="2009-07-31 12:38:24 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.3365740353291984" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="76" WEIGHT="100.0" Z="0.9609565338508114">
<NAME>Postpartum haemorrhage</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="28.200466671586646" CI_START="0.3191436547774558" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4502562952419846" LOG_CI_START="-0.49601378580265976" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-10-30 19:15:32 +0000" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="1.1432486797979036" STUDY_ID="STD-Majoko-2002a" TOTAL_1="76" TOTAL_2="76" VAR="1.3070175438596492" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.798968242838134" CI_START="0.20837812408789666" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-030.10" LOG_CI_END="0.6811478759991451" LOG_CI_START="-0.681147875999145" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-07-31 12:38:53 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="76" WEIGHT="100.0" Z="0.0">
<NAME>Fetal distress necessitating caesarean</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.798968242838134" CI_START="0.20837812408789666" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6811478759991451" LOG_CI_START="-0.681147875999145" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-05 22:02:23 +0100" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.8002192681965252" STUDY_ID="STD-Majoko-2002a" TOTAL_1="76" TOTAL_2="76" VAR="0.6403508771929823" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.914734364701076" CI_START="0.14461871523292133" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-030.11" LOG_CI_END="0.839775500980341" LOG_CI_START="-0.839775500980341" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2009-07-31 12:39:18 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="75" WEIGHT="100.0" Z="0.0">
<NAME>Apgar &lt; 5 (time unknown)</NAME>
<GROUP_LABEL_1>PGF2alpha</GROUP_LABEL_1>
<GROUP_LABEL_2>Vaginal misoprostol</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.914734364701076" CI_START="0.14461871523292133" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.839775500980341" LOG_CI_START="-0.839775500980341" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-05 22:02:45 +0100" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.9865765724632495" STUDY_ID="STD-Majoko-2002a" TOTAL_1="75" TOTAL_2="75" VAR="0.9733333333333334" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-04-14 14:25:37 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-04-14 14:25:37 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-04-14 14:24:41 +0100" MODIFIED_BY="[Empty name]">Methodological quality of trials</TITLE>
<APPENDIX_BODY MODIFIED="2008-04-14 14:25:37 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="3">
<TR>
<TH>
<P>Methodological item</P>
</TH>
<TH>
<P>Adequate</P>
</TH>
<TH>
<P>Inadequate</P>
</TH>
</TR>
<TR>
<TD>
<P>Generation of random sequence</P>
</TD>
<TD>
<P>Computer generated sequence, random number tables, lot drawing, coin tossing, shuffling cards, throwing dice.</P>
</TD>
<TD>
<P>Case number, date of birth, date of admission, alternation.</P>
</TD>
</TR>
<TR>
<TD>
<P>Concealment of allocation</P>
</TD>
<TD>
<P>Central randomisation, coded drug boxes, sequentially sealed opaque envelopes.</P>
</TD>
<TD>
<P>Open allocation sequence, any procedure based on inadequate generation.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>